Startseite Innovations in MALDI-TOF Mass Spectrometry: Bridging modern diagnostics and historical insights
Artikel Open Access

Innovations in MALDI-TOF Mass Spectrometry: Bridging modern diagnostics and historical insights

  • Anna Andreadi , Evgenia Tsivelekidou , Iasonas Dermitzakis , Paschalis Theotokis , Sofia Gargani , Soultana Meditskou und Maria Eleni Manthou EMAIL logo
Veröffentlicht/Copyright: 18. Juli 2025

Abstract

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a robust analytical technology that has become integral to biomolecular research. Since its introduction into microbiology in the early 2000s, its versatility has enabled a wide spectrum of applications extending from routine microbial identification to advanced proteomic profiling, antimicrobial resistance testing, biomarker discovery, and even historical disease investigation. In proteomics, MALDI-TOF MS has proven valuable for identifying disease-associated proteins, with applications in oncology, metabolic disorders such as diabetes and dyslipidemia, neurodegenerative diseases, hemoglobinopathies, and neonatal screening. Additionally, it has facilitated pharmacokinetic studies by enabling detailed analysis of drug distribution and metabolism. Despite limitations such as dependency on reference databases and challenges in distinguishing closely related species, ongoing advancements continue to enhance its accuracy and range. The integration of MALDI-TOF MS with molecular methods like polymerase chain reaction further strengthens its diagnostic utility. This review aims to present recent technological progress while highlighting the expanding interdisciplinary utility of MALDI-TOF MS. Emphasis is placed on emerging fields, including paleopathology, where its potential remains underexploited. By outlining its evolving capabilities, we propose a conceptual framework that positions MALDI-TOF MS as a unifying platform capable of driving innovation across diverse scientific and biomedical disciplines.

1 Introduction

Over the past two decades, medical diagnostics has witnessed a transformative evolution marked by a growing demand for rapid, reliable, and cost-efficient tools capable of accurately identifying pathogens and biomarkers [1]. The increasing burden of infectious diseases, antimicrobial resistance, and complex multifactorial conditions such as cancer and neurodegeneration has heightened the need for sophisticated diagnostic modalities that can provide timely and actionable information. Traditional culture-based and biochemical identification methods, while historically foundational, are often slow, labor-intensive, and lack the sensitivity required for modern clinical decision-making [2]. Prior to the introduction of mass spectrometry (MS) into clinical workflows, diagnostics relied heavily on time-consuming processes that delayed treatment initiation and compromised patient outcomes [3]. This diagnostic gap underscored a pressing need for technological innovation – particularly in the form of analytical platforms that could offer high-throughput, precise molecular identification with minimal sample preparation [4].

MS, originally developed as a tool for fundamental analytical chemistry, has undergone significant transformation since its inception in the early 20th century [5]. Initial mass spectrometric technologies were primarily applied in the fields of physics and chemistry to measure atomic and molecular masses [6]. However, the landscape began to shift dramatically with the advent of biological applications in the latter half of the century [7]. A pivotal breakthrough came with the development of matrix-assisted laser desorption/ionization (MALDI) and its coupling with time-of-flight (TOF) analyzers, culminating in the matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) technique [8]. This innovation provided a soft ionization method suitable for the analysis of large biomolecules, including proteins and peptides, without fragmentation. MALDI-TOF MS rapidly gained traction due to its simplicity, speed, and suitability for biomolecular profiling [9]. The foundational work of Karas, Hillenkamp, and Tanaka – recognized with the 2002 Nobel Prize in Chemistry – was instrumental in establishing MALDI-TOF MS as a viable tool for life sciences [10]. Since then, the technique has evolved from a laboratory curiosity to a clinical cornerstone in microbial identification and beyond.

Recent years have witnessed a cascade of innovations that have elevated MALDI-TOF MS beyond its initial microbial identification capabilities. Technological advancements have improved sensitivity and resolution, enabling the detection of subtle biomolecular differences and the quantification of post-translational modifications [11]. Data processing has also evolved, with artificial intelligence (AI) and machine learning algorithms now integrated into spectral analysis workflows, enhancing classification accuracy and predictive capacity [12]. MALDI-TOF MS has expanded its utility across diverse biomedical domains, including proteomics, metabolomics, biomarker discovery, oncology, pharmacokinetics, and even environmental microbiology [13]. Its transition from a single-use diagnostic tool to a multipurpose analytical platform exemplifies its growing significance. Furthermore, its role in detecting antimicrobial resistance, characterizing complex protein profiles, and enabling non-invasive liquid biopsies underscores its value in precision medicine [14].

Beyond its contemporary clinical applications, MALDI-TOF MS also embodies a fascinating confluence of historical and modern science. The technology’s core principles are deeply rooted in the heritage of analytical chemistry, where instrument-based identification has long guided scientific understanding [5]. Today, those foundational techniques have matured into robust diagnostic strategies that bridge centuries of knowledge. MALDI-TOF MS illustrates this continuity by offering tools that are simultaneously informed by traditional mass spectrometric theory and enabled by modern biomedical imperatives [15]. Moreover, its emerging role in paleopathology – facilitating the detection of ancient biomarkers and pathogens – highlights the method’s capacity to unify historical inquiry with present-day technological prowess [16]. In doing so, it strengthens our understanding of disease evolution and fosters an interdisciplinary dialogue between clinical diagnostics and archaeological science.

This review aims not only to present recent technological advances in MALDI-TOF MS but also to illuminate its expanding utility across a wide range of biomedical and interdisciplinary fields. Moving beyond its established diagnostic roles, we highlight how MALDI-TOF MS is being positioned as a versatile analytical platform with transformative potential – even in areas such as paleopathology, where its application has been largely underexplored. By tracing the evolution of its capabilities and demonstrating its relevance across both contemporary and historical biomedical contexts, this review underscores MALDI-TOF MS as a unifying tool that can bridge diverse scientific disciplines. Through this lens, we encourage researchers and clinicians to consider its applicability not only within conventional boundaries but also in uncharted scientific territories where molecular analysis may provide critical insights. In doing so, we propose a broadened conceptual framework for how MALDI-TOF MS can inform future discovery and cross-disciplinary integration.

2 Review methodology

This review, although not systematic, follows specific methodology. A meticulous research was conducted in databases like PubMed, Scopus, and Web of Science, using relevant keywords such as “MALDI-TOF MS,” “MALDI-TOF MS in paleopathology,” “MALDI-TOF MS in medicine,” “MALDI-TOF MS in microbiology,” “MALDI-TOF MS biomarkers,” and other related. In addition, the reference list of identified articles was examined for further sources. Inclusion criteria involve articles with full-text availability. The title and abstracts of the articles were assessed. Although formal quality appraisal tools were not employed, all relevant limitations, such as confounding bias, were acknowledged for transparency reasons. The key findings of the included articles are summarized to showcase in a narrative way the capability and potential MALDI-TOF MS in medical and non-medical fields.

3 MALDI-TOF MS operation principles

MALDI-TOF MS is a powerful analytical technique extensively employed in proteomics, microbiology, and clinical diagnostics for the rapid identification and characterization of biomolecules. The technique combines soft ionization with high-resolution mass analysis, enabling the detection of high-molecular-weight, fragile molecules such as proteins, peptides, and polymers while minimizing fragmentation [17]. The method relies on the use of a crystalline matrix that absorbs laser energy to facilitate the ionization of the analyte, which is then analyzed based on the time it takes to accelerate through a flight tube under vacuum [17]. In more detail, bacterial detection using MALDI-TOF MS proceeds as follows: some bacterial samples, like Gram-positive bacteria, need to be prepared before extraction [18]. On the other hand, Gram-negative bacteria can be identified directly by MS, a technique called direct cell profiling [19]. During MALDI-TOF MS analysis, samples are mixed or coated with an energy-absorbent matrix solution that ensnares and co-crystalizes them when dried [20]. When the matrix is irradiated with a laser beam (typically a nitrogen laser at a wavelength of 337 nm or a neodymium-doped yttrium-aluminum-garnet laser [Nd:YAG laser] at a wavelength of 355 nm), it absorbs its energy, generating ions that charge the analytes in the sample [20].

Matrix is an organic molecule that can absorb radiation and scatter gas molecules effectively. Common matrices include 2,5-dihydroxybenzoic acid, α-cyano-4-hydroxy-trans-cinnamic acid, and sinapinic acid [17]. The ions produced are accelerated by an electric field based on their mass-to-charge ratio (m/z) and are measured by the TOF mass analyzer. When a TOF fails to detect the target analytes in a complex mixture, a second TOF is incorporated, so that tandem mass analysis is performed [17]. A typical mass range m/z of 2–20 kDa is used, which corresponds to ribosomal and gatekeeping proteins. After TOF analysis, the peptide mass fingerprint (PMF) of the sample is produced and the PMF of an unknown organism or biomarker is compared to known database PMFs [19]. Those databases are provided by the Bruker and the Shimadzu systems and are expanding along with the machine’s increased use providing even more specific results [21]. Due to its speed, sensitivity, and minimal sample preparation requirements, MALDI-TOF MS has become an indispensable tool in both research and clinical laboratories.

4 Conventional applications of MALDI-TOF MS in medical sciences

MALDI-TOF MS has emerged as a powerful analytical platform with remarkably diverse applications across the medical sciences. Its versatility lies not only in its ability to deliver rapid and highly accurate molecular identification, but also in its adaptability to a wide range of clinical contexts – from pathogen detection and antimicrobial resistance monitoring to biomarker discovery, drug metabolism studies, and even veterinary diagnostics (Figure 1). This broad utility underscores its potential to replace or complement traditional diagnostic methods, improve patient outcomes through faster clinical decision-making, and expand precision medicine approaches. The following sections aim to demonstrate how the wide-ranging applications of MALDI-TOF MS are redefining standards in modern healthcare by providing robust, scalable, and cost-effective solutions across multiple disciplines.

Figure 1 
               Conventional applications of MALDI-TOF MS in medical sciences.
Figure 1

Conventional applications of MALDI-TOF MS in medical sciences.

4.1 Clinical microbiology

4.1.1 Identification of bacteria

One of the strengths of MALDI-TOF MS is its ability to work well with a range of different types of microbes that are usually challenging to detect using traditional methods. It has been very successful in identifying many types of bacteria: Gram-positive, Gram-negative, anaerobe, and mycobacteria, as well as in fungi species, too. MALDI-TOF MS was used to distinguish Lactobacillus plantarum by observing 34 protein markers [22]. Similarly, it has proven to be highly accurate in differentiating between related strains of clinical Streptococci, with researchers successfully identifying 99 distinct species through this approach [23]. The detection of tuberculosis through mycobacteria analysis depends heavily on MALDI-TOF MS because it can identify Mycobacterium tuberculosis [24]. The technique has also demonstrated a remarkable 95.7% accuracy in identifying anaerobic bacteria, which are often difficult to cultivate [25].

Furthermore, MALDI-TOF MS has played a role in differentiating Gram-negative bacterial rods like those belonging to the Enterobacteriaceae group, including Escherichia coli. Research conducted by Almuzara et al. demonstrated the system’s precision in recognizing species obtained from patients with cystic fibrosis [26]. Additionally, Acinetobacter species have been accurately identified through the utilization of expanded databases [27]. In the field of microbiology, this approach has proven to be very reliable in distinguishing between species of Staphylococci, making traditional coagulase tests unnecessary. Carbonelle et al. found a 97% accuracy rate in identifying coagulase-negative Staphylococci (CoNS) using the Bruker BioTyper database [28]. Meanwhile, Spanu et al. achieved a 99% precision rate when identifying subspecies, highlighting its cost-effectiveness compared to DNA sequencing [29]. While some inconsistencies still exist, improvements in reference databases and spectral matching algorithms are gradually addressing these issues.

The clinical microbiology field has experienced a transformation through MALDI-TOF MS as this technology provides rapid and precise pathogen identification across different uses. The technique allows fast bacterial pathogen detection in periprosthetic joint infections (PJIs) achieved in hours instead of the typical days required by traditional culture methods. The sensitivity of the technique improves through sonication methods, which remove bacteria from biofilm-covered prosthetic implants, thus increasing detection success rates [30]. The MALDI-TOF MS assays for alpha-defensin in synovial fluid provide a fast diagnostic solution for PJIs because they produce results in about 20 min, which helps doctors make intraoperative treatment choices.

The application of MALDI-TOF MS extends beyond orthopedic uses because it helps identify both uncommon and difficult-to-culture pathogens. The identification of Helicobacter cinaedi in immunocompromised patients becomes possible through MALDI-TOF MS which enables immediate antimicrobial therapy. The technique allows researchers to distinguish gastric Helicobacter species through their distinct protein patterns leading to better diagnostic accuracy [31]. The combination of cost-effectiveness and high-throughput capabilities establishes MALDI-TOF MS as an ideal tool for environmental monitoring within cleanroom settings to identify Bacillus species and related microbes. The system’s quick processing features enable its use in regular surveillance operations which maintain contamination control in critical environments [32]. The wide range of applications and high efficiency of MALDI-TOF MS demonstrates its essential position in present-day diagnostic procedures.

4.1.2 Identification of COVID-19 and other viruses

When it comes to virology, in 2019 the world faced a health crisis with the emergence of coronavirus disease of 2019 (COVID-19) caused by the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially, doctors used methods like polymerase chain reaction (PCR) for the diagnosis but in 2020, Nachtigall et al. came up with a method using MALDI-TOF MS analysis of nasal swabs, which showed an impressive accuracy of 93% in identifying cases from a sample size of 362, including both positive and negative cases [33]. Yan et al. extended their research by using MALDI-TOF MS to examine blood samples from individuals with COVID‐19 symptoms compared to COVID-19 patients and healthy individuals [34]. They developed a model that demonstrated 99% accuracy along with 98% sensitivity and 100% specificity. Additionally, in 2020, Wang et al. applied PCR-MALDI-TOF MS to detect SARS-CoV-2 nucleic acids. In their study, sputum and pharyngeal swab samples were analyzed for two specific genes [35]. The study revealed that SARS-CoV-2 detection by PCR-MALDI-TOF MS had high accuracy, sensitivity, and specificity and could be used in clinical settings to improve SARS-CoV-2 nucleic acids testing efficiency. At the end of 2021, Zhao et al. developed a novel strategy of a MALDI-TOF-based multiplex PCR mini-sequencing technique to identify SARS-CoV-2 variants [36]. Nine mutant types of SARS-CoV-2 variants were detected, and high specificity and an accuracy of 100% were achieved among 20 clinical verification samples. In 2022, Han et al. reported a Y-structure-induced rolling loop amplification method combined with MALDI-TOF MS for nucleic acid detection of SARS-CoV-2 with high specificity and velocity [37]. Compared with the real-time PCR test, which was the gold standard for SARS-CoV-2 early diagnosis approved by the World Health Organization (WHO), the PCR-MALDI-TOF MS-based assay had superior performance in the discrimination of SARS-CoV-2 variants [17,38].

MALDI-TOF MS was not considered the diagnostic gold standard of COVID-19. MALDI-TOF MS has shown promise in detecting SARS-CoV-2, but studies have indicated that its sensitivity may not consistently match that of reverse transcription polymerase chain reaction (RT-PCR). For example, an exploratory study using MALDI-TOF MS on saliva samples achieved an accuracy of 85.2%, which, although significant, may not be sufficient for primary diagnostic purposes [39]. In addition, implementing MALDI-TOF MS for viral detection would require significant investment in equipment and training. Given the urgency of the pandemic, using existing RT-PCR infrastructure was more feasible for timely mass testing. In addition, MALDI-TOF MS was used for detecting various viruses like polioviruses and respiratory viruses which have indicated its potential as a supporting tool for traditional virological diagnostics [7]. Recent investigations have also delved into the integration of MS with machine learning to improve the speed and cost-effectiveness of diagnosing infections. The outcomes have shown promising advancements in accuracy, following model refinement [40]. MALDI-TOF MS has proven to be successful in distinguishing viruses, like herpes simplex virus and human papillomavirus accurately in clinical virology. This method has also been effective in differentiating hepatitis B and C viruses along with influenza viruses and human immunodeficiency virus [41].

4.1.3 Identification of fungi

MALDI-TOF MS has also shown its effectiveness in identifying fungi, like yeasts and molds in environments successfully. This method allows precise identification of fungal types at a reasonable cost by comparing the mass spectra of unknown samples with established databases containing known fungal spectra. Since its incorporation into the field of mycology, MALDI-TOF MS has greatly enhanced the capability to distinguish closely related yeast species like those found in the Candida complex. These species are often challenging to differentiate using biochemical techniques [42]. Numerous research studies have emphasized the effectiveness of MALDI-TOF MS in identifying both yeasts and filamentous fungi. However, having access to databases is crucial for this identification process [43]. Recent progress has also enabled the use of MALDI-TOF MS in identifying filamentous fungi like dermatophytes, which usually present obstacles due to their intricate cell walls and varied shapes [43]. Through enhancements to the databases utilized by MALDI-TOF MS studies, MALDI-TOF MS has become a valuable tool for precisely recognizing various fungal infections [42].

MALDI-TOF MS provides an affordable option for identifying bacteria and fungi compared to the lengthy and costly process of broad-range PCR followed by sequencing. The use of MALDI-TOF MS allows for the identification of colonies in just a few minutes without the need to determine beforehand if the sample is bacterial or fungal, making it an effective method for clinical applications [44]. However, a notable drawback of MALDI-TOF MS is its requirement for pre-treatment of the sample, especially when dealing with fungi, molds, and Mycobacteria. This step not only consumes time but also calls for experienced staff and inflates the overall expenses of the diagnostic procedure. The effectiveness of MALDI-TOF MS in this context remains unclear and thus it is not commonly used in labs for cases like an athlete’s foot [45].

Nonetheless, MALDI-TOF MS has proven to be very effective in distinguishing between kinds of yeast and fungi species, as researchers found that 96% of Candida isolates from 15 different species were correctly identified using this method [46]. Moreover, two recent studies have also reported accuracy rates in yeast identification through MALDI-TOF MS, since it outperforms other conventional phenotypic methods of identifying yeast organisms by accurately telling apart various species like Candida dubliniensis and albicans as well as Cryptococcus neoformans and gattii along with other Candida complexes [44,47,48]. However, there is still little data available on how well it can differentiate molds like Aspergillus, Penicillium, Fusarium, and dermatophytes, as it was in 2017 when the first global database of fungi was created, which contained over 11,000 reference spectra from 938 fungal species, such as Aspergillus, Trichophyton, or Microsporum [49].

4.2 Establishing biomarkers

Cancer diagnosis and prognosis account for a large proportion of MALDI-TOF MS-based clinical disease diagnoses (Table 1). For example, many studies have reported the use of MALDI-TOF MS in distinguishing ovarian cancer from healthy controls. Cancer antigen 125 (CA125) is one of the two biomarkers for the diagnosis of recurrence and treatment response in ovarian cancer [17]. CA125 alone can predict ovarian cancer up to 9 months before diagnosis; however, it is not a specific cancer antigen, and it might be regulated by other benign gynecological diseases as well. Periyasamy et al. suggested that solid-phase extraction before MALDI-TOF MS analysis can improve the sensitivity of a diagnosis model to differentiate serous adenocarcinoma (a common type of epithelial ovarian cancer) and healthy controls [50]. Swiatly et al. proposed that the combined usage of isobaric tags for relative and absolute quantification (iTRAQ)-based quantitative proteomic analysis and MALDI-TOF MS can improve the differentiation of benign and malignant tumors in ovarian cancer [51].

Table 1

Diagnostic applications of MALDI-TOF MS

Cancer type Application of MALDI-TOF MS References
Ovarian cancer Distinguishing OC from healthy controls [17,50,51]
Prostate cancer Early diagnosis and biomarker discovery [17,22]
Multiple myeloma Diagnosis through Bence-Jones protein detection in urine and screening by machine learning [52,53]
Melanoma Biomarker discovery using exosomes and predicting progression [17,58]
Osteosarcoma Differentiating with/without lung metastasis [37]
Breast cancer Detection of BRC1 and BRC2 genes [5,54]
Lung cancer DNA methylation as a biomarker and other biomarkers [17,59]
Colorectal cancer Analyzation of UTP23 protein [57]

The MALDI-TOF MS technique has been used for the early diagnosis and prognosis of many other cancers including prostate cancer (PCa), liver cancer, multiple myeloma, breast cancer, pancreatic cancer, osteosarcoma, lung cancer, and colorectal cancer, too. In 2019, Long et al. proposed a MALDI-TOF MS-based approach for the diagnosis of multiple myeloma by detecting Bence-Jones proteins in human urine samples [52]. Combined with machine learning, it can be a useful screening tool of the disease [53]. In 2020, Sun et al. applied the technology of MALDI-TOF MS serum peptide fingerprinting to pre-diagnose PCa [22]. Recently, MALDI-TOF MS fingerprinting was further applied to discover lipid PCa biomarkers in urine samples from 121 PCa patients and 18 healthy controls [17]. Scientists have also achieved the identification of breast cancer gene 1 (BRC1) and breast cancer gene 2 (BRC2) copies through MALDI-TOF MS in 2023 which demonstrated better sensitivity than targeted next-generation sequencing at equivalent cost [54]. The exosome fingerprinting method using MALDI-TOF MS showed excellent sensitivity for pancreatic cancer detection which indicates its potential as a monitoring tool for this cancer type [55]. The same technique has also been applied to the diagnosis of osteosarcoma using non-invasive liquid biopsy [37]. Li et al. used MALDI-TOF MS to analyze serum samples and proposed multiple candidates for lung cancer biomarkers to evaluate chemotherapy effectiveness [56]. Researchers have also used MALDI-TOF MS to analyze UTP23 protein which promotes colorectal cancer progression thus demonstrating its value in cancer research [57].

On the mature foundation of MALDI-TOF MS fingerprinting technology, many other samples have been used for biomarker discovery and cancer diagnosis, especially exosomes isolated from body fluids. In 2019, Zhu et al. used MALDI-TOF MS to analyze exosomes extracted from the serum of melanoma patients and healthy donors and demonstrated that the mass fingerprinting of bloodstream-circulating exosomes can be used for cancer diagnosis and monitoring [58]. In 2021, Han et al. successfully used MALDI-TOF MS to analyze serum exosomes from patients with osteosarcoma with and without lung metastasis and healthy controls [37]. In 2021, cells collected from the surface of suspected skin areas were used by Zhu et al. to detect melanoma and predict skin disorder progression [58]. Non-invasive sampling is another advantage of this study considering the benign method of obtaining cells from the skin surface [17]. DNA methylation is another potential biomarker for several cancers with close relatedness to tumorigenesis, development, and cell carcinogenesis. Ehrich et al. used the method to quantify methylation differences between normal and neoplastic lung cancer tissue samples [59].

Furthermore, MALDI-TOF MS can potentially be used for neonatal screening for various diseases, such as phenylketonuria, homocystinuria, maple syrup urine disease, and sickle cell anemia. Kim et al. found that parylene matrix chips in combination with MALDI-TOF MS are an approach to testing babies for metabolic conditions, such as phenylketonuria and maple syrup urine disease [60]. Despite some challenges in the extracting efficiency encountered in this process, the technique demonstrates consistency and accuracy levels rendering it a valuable asset for precise diagnosis in medical facilities [60]. In a pilot screening study for sickle cell anemia that took place in France, researchers managed to differentiate between heterozygous fetal hemoglobin (F), sickle hemoglobin (S), and hemoglobin E (FSE), fetal hemoglobin (F), sickle hemoglobin (S), and hemoglobin O-Arab (FSO-Arab) and β-thalassemia trait (S-β+) samples and heterozygous fetal hemoglobin, adult hemoglobin, and sickle cell hemoglobin (FAS) and homozygous fetal hemoglobin (F) and hemoglobin S (FS) samples [61]. Furthermore, a prospective study in 2024 concluded that the sensitivity and specificity of the method reached 100% [62]. The MALDI-TOF MS system allows the detection of fetal hemoglobin (Hb-F) variants and exact diagnosis and classification of β-thalassemia which assists in personalized treatment of β-thalassemia [63]. Furthermore, researchers have developed an MS/MS Hemo kit for the detection of sickle cell anemia with almost 100% sensitivity and specificity [64]. MALDI-TOF MS was proven to be a cost- and time-effective asset that enabled its approval for screening populations [61].

Biomarkers for diabetes mellitus are also targets of MALDI-TOF MS. Meng et al. identified six peptides linked to diabetes mellitus type 2 that can differentiate patients from healthy controls with an accuracy of 82.20%, a sensitivity of 82.50%, and a specificity of 77.80% [65]. The distinction between type 1 and type 2 diabetes can also be achieved, as MALDI-TOF MS can detect the quantities of C-reactive protein, which represents the amount of insulin in the body [66]. In 2021, Zawada et al. attempted to further investigate the protein profile of type 1 diabetes patients with certain characteristics (increased adipose tissue, decreased control of the disease, and chronic complications) and concluded that increased levels of C3, C4, and fibrinogen should be taken into consideration when it comes to the disease [67]. Recent studies have shown that MALDI-TOF MS technology shows promise for individualized diabetes treatment and diabetic microangiopathy genetic factor investigation [68]. MALDI-TOF MS has been proven useful in recent studies for detecting protein-related molecules linked to hyperlipidemia, which demonstrates its potential as a biomarker for disease diagnosis and research [69].

Alzheimer’s disease (AD) is a neurodegenerative disease and in the early phase of its discovery, AD biomarkers, cerebrospinal fluid (CSF), a proximal fluid, was often studied. According to a review, the most characteristic AD biomarkers in CSF are β-amyloid (βA), tau protein, and phospho-tau [70]. In 1993, the first study of targeted βA proteomics found multiple βA isoforms in CSF with the use of MALDI-TOF MS [71]. In 2018, Nakamura et al. found a new composite biomarker, βA precursor protein (APP), to predict positive or negative brain βA based on MALDI-TOF MS analysis, illustrating the high performance of plasma biomarkers in brain βA burden prediction and AD diagnosis [72]. In 2021, Shimadzu released a MALDI-based amyloid mass spectrometry with a centiloid system (amyloid MS CL system) for testing the levels of amyloid peptides in the blood that are associated with AD [17]. The application of MALDI-TOF MS as a screening tool for spinal muscular atrophy and for identifying biomarkers of neuropathic pain has been proposed [73,74]. MALDI-TOF MS is nowadays capable of identifying novel biomarkers for Hashimoto thyreoiditis and osteoarthritis, too [75,76].

4.3 Detection of antibiotic resistance

MALDI-TOF MS has proven effective in detecting antibiotic resistance. Its quick and accurate detection abilities offer information for care and community health measures. MALDI-TOF MS plays a role in enhancing antimicrobial susceptibility testing by swiftly detecting resistance mechanisms compared to the conventional methods – providing results up to 24 h earlier than usual methods would offer. This technology can pinpoint resistance through approaches such as analyzing compounds and examining antimicrobial molecules, changes in bacterial cell wall, ribosomal RNA methylation, and mutations. Its applications are diverse, including detection of carbapenemase activity within 2 h and identifying colistin resistance by studying lipid A biomarkers [7]. Some of the accomplishments of this method include targeting B lactamases and methicillin-resistant Staphylococcus aureus in addition to the carbapenemase gene (cfiA gene) in Bacteroides fragilis and vancomycin-resistant Enterococcus [77,78,79]. In 2018, Zhu and colleagues altered the material used in MALDI-TOF MS testing to analyze extended-spectrum β-lactamase-producing E. coli, multidrug-resistant Pseudomonas aeruginosa, and methicillin-resistant S. aureus using intact bacteria [58].

4.4 Study of drug metabolism

MALDI-TOF MS is a valuable tool in research that aids accurately and sensitively in examining drug substances and their byproducts in biological samples and in comprehending the processes related to absorption, distribution, metabolism, excretion, and toxicity. Its use has become widespread for examining how drugs are distributed within tissues without the requirement of labeling them specifically. This helps localize and measure drug components accurately with resolution in pharmacokinetic investigations [80,81]. This method enables scientists to chart the spread of drugs and their byproducts in tissues and gain insight into the effects and potential dangers of the medication [80].

Additionally, Swales et al. demonstrated the utility of MALDI-TOF MS in cassette dosing strategies, which enable the simultaneous administration and analysis of multiple drugs in preclinical pharmacokinetic studies [81]. This method decreases animal testing while boosting biodistribution analysis throughput which leads to more efficient drug discovery processes. MALDI-TOF MS works together with drug efficacy study implementation and liquid extraction surface analysis MS imaging techniques to provide complete drug distribution detection and analysis. Herkt et al. utilized MALDI-TOF MS for the pharmacokinetic study of antisense oligonucleotides [82]. The technique enabled the identification and measurement of therapeutic oligonucleotides in biological samples with a focus on plasma analysis. This is crucial for the advancement of treatments that target materials like antisense oligonucleotides for ailments such as cardiac hypertrophy. MALDI-TOF MS is also utilized for examining how drugs bind to proteins and analyzing metabolites in pharmacokinetics. This contributes to the identification of drug–protein connections, the monitoring of drug stability, and the interactions with molecules during the distribution and metabolism stages of pharmacokinetics [82].

In general, MALDI-TOF MS greatly improves the accuracy of research by delivering detailed and simultaneous identification of medications and their byproducts in biological samples without labels. This aids in improving comprehension of how drugs act in the body, resulting in informed choices throughout the drug development. The antioxidant and anticancer effects of natural extracts, such as those from Verbascum thapsus, have been explored using MALDI-TOF MS, further demonstrating its relevance in pharmacological studies and reinforcing the technique’s capability to analyze complex biological samples and contribute to drug development [83]. Additionally, recent researches in herbal medicines have utilized MALDI-TOF MS to illustrate signaling pathways related to drug action [84].

4.5 Proteomics

MALDI-TOF MS has undergone advancements in its use for proteomics over the years. Initially, in 2006, it became a tool for quickly identifying proteins in large quantities [85]. By 2007, advancements in high-performance systems improved its sensitivity and speed, making it a popular choice for studying proteins and peptides in proteomic research, and in 2011, bacterial species were identified through protein profiling [86]. This method became a practice in microbial diagnostics leading to 2015 when these advancements were further expanded to benefit the health field by aiding in the identification of bacteria and enhancing the understanding of antimicrobial resistance [85,87]. In 2016, and beyond that time frame, especially in 2018 and 2022, MALDI-TOF MS technology made progress in exploring proteomics with a specific focus in mind, incorporating MALDI Fourier transform ion cyclotron resonance for an in-depth view of proteins in tissues to facilitate studies into the spatial distribution of proteins within intricate diseases, like cancer and cystic fibrosis [87]. Further enhancements occurred when the method was employed for pathogen identification and biomarker discovery purposes. This involved analyzing proteins and utilizing bioinformatics for more precise diagnostics [85,86]. In conclusion, MALDI-TOF MS has made significant contributions in the field of proteomics, ranging from basic protein identification to innovative uses in spatial proteomics and the discovery of pathogen biomarkers.

4.6 Veterinary medicine

Veterinary medicine also recognizes MALDI-TOF MS as a valuable diagnostic tool. The analysis of fungus detection combined with antimicrobial resistance testing and biofilm formation evaluation and heart disease biomarkers can be detected using MALDI-TOF MS [88,89,90]. The combination of MALDI-TOF MS with human pathogen databases through web applications enables precise detection of animal fungal infections [91]. The application of human pathogen databases in veterinary medicine demonstrates both the necessity and capability for interdisciplinary MALDI-TOF MS use to expand its functionality beyond current database constraints.

5 Expanding the application horizons of MALDI-TOF MS: A prism into paleopathology

MALDI-TOF MS has transitioned from an experimental concept to a practical application in paleopathology (Table 2), (Figure 2). MALDI-TOF MS provides proteomic analysis through its stable molecular framework because PCR-based methods depend on the fragile and often degraded nucleic acids [17]. The method works best in extreme environmental settings because it recovers DNA when other methods fail [92].

Table 2

Summary of palaeopathological research with MALDI-TOF MS

Samples Trait identified References
Archaeological bone samples Mycobacterium tuberculosis [93]
Morphologically “healthy” human skeletal remains Mycobacterium tuberculosis [94]
Skeleton that presented evidence of tuberculous spondylitis in the Roman Period Mycobacterium tuberculosis [95]
Ancient, fragmented skeleton with osteogenic sarcoma/various infected and morphologically “healthy” human skeletal remains Osteosarcoma and Mycobacterium tuberculosis [102]
Coprolite in a closed Medieval barrel 15 different bacterial species of intestinal flora [101]
Skeletal remains from indigenous Caribbean people Plasmodium falciparum [98]
Figure 2 
               Non-medical applications of MALDI-TOF MS.
Figure 2

Non-medical applications of MALDI-TOF MS.

In 2010, MALDI-TOF MS was used in a study to detect the presence of ancient mycolic acids from archaeological bone samples. It appeared to be a high-throughput and highly sensitive method for the molecular analysis of paleopathological remains infected by the M. tuberculosis. This was the first time that MALDI-TOF MS was demonstrated as a useful technique in the field of paleoanthropological investigations [93].

In 2011, the first study to show that the MS-based protein analysis of ancient proteins is a powerful technique for paleopathological examinations was executed with the identification of ancient mycobacterial proteins on infected and morphologically “healthy” human skeletal remains. Several mycobacterial proteins have been extracted and identified by MALDI-TOF MS from archaeological human skeletal remains since then [94,95]. It is worth mentioning, too, that given previous studies, MALDI-TOF MS not only successfully identifies ancient mycolic acids and proteins but also distinguishes M. tuberculosis from Mycobacterium leprae. According to the researchers, even though it has not been used in ancient bones, it is time to examine bones with evidence of leprosy and positive ancient DNA with the use of MALDI-TOF MS [96].

In 2023, Plasmodium falciparum was successfully identified in contemporary blood samples, facilitating research for other subspecies on a clinical basis [97]. However, beforehand, in 2017, Inwood J. had already written a thesis intending to create a method for the detection of P. falciparum infection [98]. A combination of three techniques was used: electron microscopy, X-ray diffraction, and MALDI-TOF MS and for the first time, detection of hemozoin in ancient remains was carried out. Hemozoin is a biomolecule produced by all Plasmodium species and is a promising biomarker for the identification of malaria both in living blood samples and ancient skeletal remains [98]. Although MALDI-TOF MS has not been used yet for the detection of Yersinia pestis in paleopathological findings, it has nevertheless been successfully used in modern clinical samples [68,99]. Antibodies of Y. pestis have been detected in ancient dental pulp using immunological techniques instead [100]. A coprolite found in 1996 inside a closed medieval barrel in the Namur region of Belgium underwent a multi-level analysis which included microscopy, culture, MALDI-TOF MS identification of colonies, and metagenomic analysis to determine the intestinal microbiome. The MALDI-TOF MS identification revealed 15 different bacterial species [101]. The MALDI-TOF MS use expanded successfully in 2014 from contemporary samples to the identification of protein biomarkers for osteosarcoma from a 2,000-year-old female skeleton excavated from Hungary. Up to 60 proteins were detected, among which many related to oncogenesis. The same study also managed to identify protein biomarkers of M. tuberculosis [102].

6 Translating the applications of MALDI-TOF MS beyond medicine

The aquaculture industry has adopted MALDI-TOF MS as a powerful identification tool as it provides faster results at lower costs than traditional bacterial identification techniques. The identification process of V. anguillarum together with rainbow trout pathogens Aeromonas salmonicida, Flavobacterium psychrophilum, Yersinia ruckeri, Streptococcus agalactiae, Streptococcus iniae, Aeromonas hydrophila, and Aeromonas veronii can be achieved through an efficient and cost-effective alternative method using MALDI-TOF MS [24,25,57,58]. MALDI-TOF MS has gained widespread acceptance in species-level identification and antibiotic resistance testing of aquatic pathogens during the last 10 years [103]. Indeed, with the use of MALDI-TOF MS, mussel foot proteins with strong adhesive properties were identified [104]! The implementation of MALDI-TOF MS technology has brought substantial improvements to food quality control and safety assessment procedures as well. The detection system based on MALDI-TOF MS has been implemented to verify Mozzarella di Bufala Campana cheese authenticity while protecting consumer safety [105]. The analysis of broiler chicken breast meat through MALDI-TOF MS during refrigerated storage revealed the progressive growth of Pseudomonas species numbers throughout storage time [106]. Additionally, MALDI-TOF MS has assisted in bacterial pesticide analysis to study their operational mechanisms and evaluate their potential to contaminate food products and detect remaining residues [107].

7 Future directions and current limitations of MALDI-TOF MS

In recent years, advances in MS have transformed microbial diagnostics, with MALDI-TOF MS emerging as a compelling alternative to traditional molecular methods. Specifically, MALDI-TOF MS offers an alternative to PCR, a standard method in today’s clinical and research praxis, with the advantages of speediness, cost efficiency, and ease of sample preparation [108]. Regarding the identification of substances or microorganisms in clinical scenarios, MALDI-TOF MS has proven valuable for making quick decisions about patient care needs [109], since it can pinpoint an isolate in 6 min while PCR usually requires more time due to its amplification steps and potential sequencing requirements. Moreover, MALDI-TOF MS is a budget-friendly option as it can cut costs by up to 32% in contrast to traditional techniques because of its inexpensive supplies and simplified procedure, particularly suited for extensive clinical microbiology labs, unlike PCR, which demands expensive materials and machinery [44]. MALDI-TOF MS has also benefits when it comes to preparing samples because it can pinpoint pathogens directly from samples without the requirement of culturing them first [18,44]. This proves to be particularly advantageous not only for diagnostics but for reducing sample damage, as well, especially when dealing with precious ancient samples. While PCR outshines in detecting hard-to-culture organisms and spotting resistance genes, MALDI-TOF MS is progressing in this realm by detecting proteins linked to resistance-like strains that produce carbapenemase [14]. MALDI-TOF MS stands out as a choice for quick and budget-friendly identification of microbes compared to PCR, which shines in genetic analysis and detecting resistance factors [44,110].

Beyond microbial identification, MALDI-TOF MS is gaining traction as a multifaceted tool in both clinical and research environments, offering applications that extend well into antimicrobial stewardship and disease biomarker discovery. Interestingly, MALDI-TOF MS generally provides precise microorganism identification that outperforms conventional biochemical and molecular techniques in terms of speed, cost-effectiveness, and convenience [108]. It plays a key role in combating the escalating threat of antimicrobial resistance by swiftly pinpointing antibiotic resistance and identifying different microbial species with accuracy and efficiency in crucial situations [111]. Additionally, the ability of MALDI-TOF MS to support susceptibility testing by identifying resistance mechanisms early on compared to traditional approaches highlights its crucial role in combating resistant infections [112]. In the field of proteomics, MALDI-TOF MS has made progress in identifying proteins linked to diseases like cancer and diabetes. This advancement has improved our knowledge of disease processes and opened up possibilities for personalized medical treatments [68]. Notably, it is excelling in discovering biomarkers of promising new diagnostic methods for various illnesses. Through offering in-depth profiles and analysis data from MALDI-TOF MS, technology is not just beneficial for early detection purposes but also enables more accurate disease prognosis and monitoring capabilities to be established.

The application of MALDI-TOF MS technology in paleopathology opens new possibilities to study ancient diseases through different perspectives. The technology demonstrates its versatility through its ability to detect pathogens including M. tuberculosis and P. falciparum [98,102]. The examination of samples combined with historical disease trend analysis enables scientists to understand pathogen evolution while revealing their complex host-pathogen interactions across time. The example of plasmodium identification for paleopathological purposes before clinical purposes demonstrates how MALDI-TOF MS expansion across multiple fields accelerates its development [100]. Researchers from paleopathology and clinical microbiology who share common targets can achieve faster mutual discoveries through collaborative work. The field of comparative proteomic epidemiology shows great promise because it allows scientists to study evolutionary patterns by matching ancient pathogen spectra with modern equivalents [16]. The validation and optimization of protocols require essential collaboration between archaeological sciences and biomedical labs particularly for sample preparation and preservation assessment and database enrichment.

Although MALDI-TOF MS has become a gold standard in routine microbial identification and is increasingly implemented in clinical and research settings, it remains relatively underrecognized outside specialized laboratories when compared to other diagnostic technologies, such as PCR and next-generation sequencing [7]. This may be partly due to its relatively recent integration into clinical workflows, the requirement for specialized instrumentation and technical expertise, and the misconception that its applications are limited to microbiology [7]. Nevertheless, MALDI-TOF MS offers remarkable advantages, including rapid turnaround time, cost-effectiveness, and the ability to analyze a wide variety of biological samples with minimal preparation [113]. Importantly, it is not without its limitations. The performance of the technique is highly dependent on the quality and comprehensiveness of reference spectral databases, which currently lack sufficient representation of rare, fastidious, or unculturable organisms [113]. Moreover, the system still struggles to distinguish between closely related species and subspecies, as exemplified by the ongoing difficulty in differentiating Shigella species from E. coli [114,115]. Hygiene concerns and the risk of contamination may also be relevant in certain settings, although these are manageable through standardized cleaning protocols [116].

Despite these challenges, these limitations are not intrinsic to the technology and can be progressively addressed through continuous use, interdisciplinary collaboration, and expanded database curation. A key future direction lies in the enhancement of reference databases through the inclusion of high-quality spectra from diverse biological sources, contributed by a wide network of laboratories across multiple disciplines. In parallel, improvements in bioinformatics tools, including machine learning algorithms for pattern recognition, are expected to refine species- and strain-level discrimination. Furthermore, the potential of MALDI-TOF MS extends well beyond microbial diagnostics. Its versatility is increasingly demonstrated across diverse scientific domains such as paleopathology, environmental microbiology, aquaculture, oncology (e.g., detection of tumor-specific antigens), and biomarker discovery. These interdisciplinary applications underscore the need for strategic investment and broader recognition of MALDI-TOF MS as a central analytical platform. Its cost-effectiveness and high throughput make it especially attractive for use in resource-limited settings and large-scale screening programs.

MALDI-TOF MS is being positioned as a versatile analytical platform with transformative potential – even in areas such as paleopathology, where its application has been largely underexplored. By tracing the evolution of its capabilities and demonstrating its relevance across both contemporary and historical biomedical contexts, this review underscores MALDI-TOF MS as a unifying tool that can bridge diverse scientific disciplines. Through this lens, we encourage researchers and clinicians to consider its applicability not only within conventional boundaries but also in uncharted scientific territories where molecular analysis may provide critical insights. In doing so, we propose a broadened conceptual framework for how MALDI-TOF MS can inform future discovery and cross-disciplinary integration. To maximize its potential, MALDI-TOF MS should be adopted in parallel with established molecular techniques such as PCR, at least during the transition phase, to ensure diagnostic reliability and to facilitate the validation of its expanded use. As cumulative datasets grow and cross-disciplinary spectral overlap increases, the reliability and discriminatory power of the technique are expected to improve significantly.

Ultimately, the future of MALDI-TOF MS depends on sustained research, institutional support, and integration into routine workflows across various scientific and clinical domains. With targeted funding, enhanced inter-laboratory collaboration, and technological advancements, many of its current drawbacks can be overcome. This will not only strengthen its diagnostic utility but also unlock new avenues for research and innovation, making MALDI-TOF MS a cornerstone of precision diagnostics in the years to come.

8 Conclusions

MALDI-TOF MS has emerged as a transformative analytical platform with broad applicability across diverse scientific domains. Its ability to deliver rapid, accurate, and cost-effective molecular identifications has revolutionized clinical microbiology and is now gaining traction in fields previously considered outside its traditional scope, such as paleopathology. This review highlights the evolving capabilities of MALDI-TOF MS, tracing its development from a diagnostic tool in contemporary medicine to a key asset in historical biomolecular research. By demonstrating its relevance across both modern and ancient biomedical contexts, we position MALDI-TOF MS as a unifying technology that can bridge disciplinary divides. As advancements in AI integration, direct-from-sample processing, and bioinformatics continue to enhance its clinical utility, MALDI-TOF MS is also poised to redefine the analytical possibilities in paleoproteomics. However, realizing its full potential requires addressing current limitations, particularly the need for standardized spectral databases, improved taxonomic resolution, and refined protocols for handling minute or degraded samples. We advocate for a conceptual shift in how this technology is perceived – encouraging its adoption not only within established diagnostic frameworks but also in underexplored scientific frontiers. Thereby, MALDI-TOF MS may become a cornerstone for future discovery, innovation, and interdisciplinary integration.


# These authors contributed equally to this work.


  1. Funding information: Authors state no funding involved.

  2. Author contributions: M.E.M. and S.M. conceptualized the review and supervised the overall structure and writing process. E.T. and A.A. conducted the literature search and selected relevant articles. Data curation and analysis were carried out by E.T., A.A., I.D., S.G., and P.T. The original draft of the manuscript was prepared by I.D., E.T., and A.A. M.E.M., S.G., and I.D. revised and edited the manuscript. Visualization and preparation of figures and tables were performed by I.D., E.T., and A.A. All authors have read and approved the final version of the manuscript.

  3. Conflict of interest: Authors state no conflict of interest.

  4. Data availability statement: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

[1] Nakhod V, Krivenko A, Butkova T, Malsagova K, Kaysheva A. Advances in molecular and genetic technologies and the problems related to their application in personalized medicine. J Pers Med. 2024 May;14(6):555.10.3390/jpm14060555Suche in Google Scholar PubMed PubMed Central

[2] Franco-Duarte R, Černáková L, Kadam S, Kaushik KS, Salehi B, Bevilacqua A, et al. Advances in chemical and biological methods to identify microorganisms-from past to present. Microorganisms. 2019 Dec;7(5):130.10.3390/microorganisms7050130Suche in Google Scholar PubMed PubMed Central

[3] Swiner DJ, Jackson S, Burris BJ, Badu-Tawiah AK. Applications of mass spectrometry for clinical diagnostics: The influence of turnaround time. Anal Chem. 2020 Jan;92(1):183–202.10.1021/acs.analchem.9b04901Suche in Google Scholar PubMed PubMed Central

[4] Mojebi A, Wu P, Keeping S, Hale B, Chase JG, Beaubrun A. Clinical impact of rapid molecular diagnostic tests in patients presenting with viral respiratory symptoms: A systematic literature review. PLoS One. 2024;19(6):e0303560.10.1371/journal.pone.0303560Suche in Google Scholar PubMed PubMed Central

[5] Yates Iii RJ. A century of mass spectrometry: From atoms to proteomes. Nat Methods. 2011 Aug;8(8):633–7.10.1038/nmeth.1659Suche in Google Scholar

[6] Tőkés L. The allure of mass spectrometry: From an earlyday chemist’s perspective. Mass Spectrom Rev. 2017;36(4):520–42.10.1002/mas.21499Suche in Google Scholar PubMed PubMed Central

[7] Calderaro A, Chezzi C. MALDI-TOF MS: A reliable tool in the real life of the clinical microbiology laboratory. Microorganisms. 2024 Feb;12(2):322.10.3390/microorganisms12020322Suche in Google Scholar PubMed PubMed Central

[8] Tanaka K, Waki H, Ido Y, Akita S, Yoshida Y, Yoshida T, et al. Protein and polymer analyses up to m/z 100 000 by laser ionization time‐of‐flight mass spectrometry. Rapid Communications in Mass Spectrom. 1988;2:151–3. Wiley Online Library [Internet]. [cited 2025 May 8]. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/rcm.1290020802. 10.1002/rcm.1290020802Suche in Google Scholar

[9] Fenselau C, Demirev PA. Characterization of intact microorganisms by maldi mass spectrometry. Mass Spectrom Rev. 2001;20(4):157–71.10.1002/mas.10004Suche in Google Scholar PubMed

[10] Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem. 1988 Oct;60(20):2299–301.10.1021/ac00171a028Suche in Google Scholar PubMed

[11] DeLaney K, Phetsanthad A, Li L. Advances in high-resolution maldi mass spectrometry for neurobiology. Mass Spectrom Rev. 2022 Mar;41(2):194–214.10.1002/mas.21661Suche in Google Scholar PubMed PubMed Central

[12] Beck AG, Muhoberac M, Randolph CE, Beveridge CH, Wijewardhane PR, Kenttämaa HI, et al. Recent developments in machine learning for mass spectrometry. ACS Meas Sci Au. 2024 Jun;4(3):233–46.10.1021/acsmeasuresciau.3c00060Suche in Google Scholar PubMed PubMed Central

[13] Tarfeen N, Nisa KU, Nisa Q. MALDI-TOF MS: Application in diagnosis, dereplication, biomolecule profiling and microbial ecology. Proc Indian Natl Sci Acad Part Phys Sci. 2022;88(3):277–91.10.1007/s43538-022-00085-2Suche in Google Scholar

[14] Cheon DH, Jang H, Choi YK, Oh WS, Hwang S, Park JR, et al. Clinical evaluation of advanced MALDI-TOF MS for carbapenemase subtyping in Gram-negative isolates. J Clin Microbiol. 2025 Jan;63(1):e0147524.10.1128/jcm.01475-24Suche in Google Scholar PubMed PubMed Central

[15] Hou TY, Chiang-Ni C, Teng SH. Current status of MALDI-TOF mass spectrometry in clinical microbiology. J Food Drug Anal. 2019 Apr;27(2):404–14.10.1016/j.jfda.2019.01.001Suche in Google Scholar PubMed PubMed Central

[16] Warinner C, Korzow Richter K, Collins MJ. Paleoproteomics. Chem Rev. 2022 Aug 24;122(16):13401–46.10.1021/acs.chemrev.1c00703Suche in Google Scholar PubMed PubMed Central

[17] Li D, Yi J, Han G, Qiao L. MALDI-TOF mass spectrometry in clinical analysis and research. ACS Meas Sci Au. 2022;2:385–404. [Internet]. [cited 2024 May 23]. https://pubs.acs.org/doi/full/10.1021/acsmeasuresciau.2c00019. 10.1021/acsmeasuresciau.2c00019Suche in Google Scholar PubMed PubMed Central

[18] Smole SC, King LA, Leopold PE, Arbeit RD. Sample preparation of Gram-positive bacteria for identification by matrix assisted laser desorption/ionization time-of-flight. J Microbiol Methods. 2002 Feb;48(2):107–15.10.1016/S0167-7012(01)00315-3Suche in Google Scholar PubMed

[19] Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI-TOF mass spectrometry: An emerging technology for microbial identification and diagnosis. Front Microbiol. 2015 Aug;6:791.10.3389/fmicb.2015.00791Suche in Google Scholar PubMed PubMed Central

[20] Leopold J, Popkova Y, Engel KM, Schiller J. Recent developments of useful MALDI matrices for the mass spectrometric characterization of lipids. Biomolecules. 2018 Dec;8(4):173.10.3390/biom8040173Suche in Google Scholar PubMed PubMed Central

[21] Carbonnelle E, Grohs P, Jacquier H, Day N, Tenza S, Dewailly A, et al. Robustness of two MALDI-TOF mass spectrometry systems for bacterial identification. J Microbiol Methods. 2012 Dec;89(2):133–6.10.1016/j.mimet.2012.03.003Suche in Google Scholar PubMed

[22] Sun J, Yu G, Yang Y, Qiao L, Xu B, Ding C, et al. Evaluation of prostate cancer based on MALDI-TOF MS fingerprinting of nanoparticle-treated serum proteins/peptides. Talanta. 2020 Dec;220:121331.10.1016/j.talanta.2020.121331Suche in Google Scholar PubMed

[23] Friedrichs C, Rodloff AC, Chhatwal GS, Schellenberger W, Eschrich K. Rapid identification of viridans streptococci by mass spectrometric discrimination. J Clin Microbiol. 2007 Aug;45(8):2392–7.10.1128/JCM.00556-07Suche in Google Scholar PubMed PubMed Central

[24] Buckwalter SP, Olson SL, Connelly BJ, Lucas BC, Rodning AA, Walchak RC, et al. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Mycobacterium species, Nocardia species, and other aerobic Actinomycetes. J Clin Microbiol. 2016 Feb;54(2):376–84.10.1128/JCM.02128-15Suche in Google Scholar PubMed PubMed Central

[25] Alcalá L, Marín M, Ruiz A, Quiroga L, Zamora-Cintas M, Fernández-Chico MA, et al. Identifying anaerobic bacteria using MALDI-TOF mass spectrometry: A four-year experience. Front Cell Infect Microbiol. 2021 Apr;11:521014.10.3389/fcimb.2021.521014Suche in Google Scholar PubMed PubMed Central

[26] Almuzara M, Barberis C, Traglia G, Famiglietti A, Ramirez MS, Vay C. Evaluation of matrix-assisted laser desorption ionization-time-of-flight mass spectrometry for species identification of Nonfermenting Gram-Negative Bacilli. J Microbiol Methods. 2015 May;112:24–7.10.1016/j.mimet.2015.03.004Suche in Google Scholar PubMed

[27] Jeong S, Hong JS, Kim JO, Kim KH, Lee W, Bae IK, et al. Identification of acinetobacter species using matrix-assisted laser desorption ionization-time of flight mass spectrometry. Ann Lab Med. 2016 Jul;36(4):325–34.10.3343/alm.2016.36.4.325Suche in Google Scholar PubMed PubMed Central

[28] Carbonnelle E, Beretti JL, Cottyn S, Quesne G, Berche P, Nassif X, et al. Rapid identification of Staphylococci isolated in clinical microbiology laboratories by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2007 Jul;45(7):2156–61.10.1128/JCM.02405-06Suche in Google Scholar PubMed PubMed Central

[29] Spanu T, De Carolis E, Fiori B, Sanguinetti M, D’Inzeo T, Fadda G, et al. Evaluation of matrix-assisted laser desorption ionization-time-of-flight mass spectrometry in comparison to rpoB gene sequencing for species identification of bloodstream infection staphylococcal isolates. Clin Microbiol Infect. 2011 Jan 1;17(1):44–9.10.1111/j.1469-0691.2010.03181.xSuche in Google Scholar PubMed

[30] Sandu EC, Cursaru A, Iordache S, Serban B, Costache MA, Cirstoiu C. Utility of matrix-assisted laser desorption ionization time-of-flight mass spectrometry in periprosthetic joint infection diagnosis. Cureus. 2024 Oct;16(10):e70650.10.7759/cureus.70650Suche in Google Scholar PubMed PubMed Central

[31] Yamamoto K, Ono D, Nozaki Y, Nishida Y, Sakai J, Mimura K, et al. A case of Helicobacter cinaedi pleuritis and continuous ambulatory peritoneal dialysis-related peritonitis diagnosed by simultaneous-onset bacteremia. IDCases. 2025;40:e02197.10.1016/j.idcr.2025.e02197Suche in Google Scholar PubMed PubMed Central

[32] Mazhari F, Regberg AB, Castro CL, LaMontagne MG. Resolution of MALDI-TOF compared to whole genome sequencing for identification of Bacillus species isolated from cleanrooms at NASA Johnson Space Center. Front Microbiol. 2025;16:1499516.10.3389/fmicb.2025.1499516Suche in Google Scholar PubMed PubMed Central

[33] Nachtigall FM, Pereira A, Trofymchuk OS, Santos LS. Detection of SARS-CoV-2 in nasal swabs using MALDI-MS. Nat Biotechnol. 2020 Oct;38(10):1168–73.10.1038/s41587-020-0644-7Suche in Google Scholar PubMed

[34] Yan L, Yi J, Huang C, Zhang J, Fu S, Li Z, et al. Rapid detection of COVID-19 using MALDI-TOF-based serum peptidome profiling. Anal Chem. 2021 Mar;93(11):4782–7.10.1021/acs.analchem.0c04590Suche in Google Scholar PubMed

[35] Wang J, Zhang D, Chen Q, Yu J, Yang Y, Qiao L, et al. Establishment and application of PCR-time-of-flight mass spectrometer for SARS-CoV-2 nucleic acid detection. Chin Gen Pract. 2020 Dec;23(35):4430.Suche in Google Scholar

[36] Zhao Z, Sun L, Wang L, Li X, Peng J. A multiplex method for detection of SARS-CoV-2 variants based on MALDI-TOF mass spectrometry. Biosaf Health. 2023 Apr;5(2):101–7.10.1016/j.bsheal.2023.02.003Suche in Google Scholar PubMed PubMed Central

[37] Han Z, Yi J, Yang Y, Li D, Peng C, Long S, et al. SERS and MALDI-TOF MS based plasma exosome profiling for rapid detection of osteosarcoma. Analyst. 2021 Oct;146(21):6496–505.10.1039/D1AN01163DSuche in Google Scholar

[38] Rybicka M, Miłosz E, Bielawski KP. Superiority of MALDI-TOF mass spectrometry over real-time PCR for SARS-CoV-2 RNA detection. Viruses. 2021 May;13(5):730.10.3390/v13050730Suche in Google Scholar PubMed PubMed Central

[39] Costa MM, Martin H, Estellon B, Dupé FX, Saby F, Benoit N, et al. Exploratory study on application of MALDI-TOF-MS to detect SARS-CoV-2 infection in human saliva. J Clin Med. 2022 Jan;11(2):295.10.3390/jcm11020295Suche in Google Scholar PubMed PubMed Central

[40] Yegorov S, Kadyrova I, Korshukov I, Sultanbekova A, Kolesnikova Y, Barkhanskaya V, et al. Application of MALDI-TOF MS and machine learning for the detection of SARS-CoV-2 and non-SARS-CoV-2 respiratory infections. Microbiol Spectr. 2024 Dec;12(5):e0406823.10.1128/spectrum.04068-23Suche in Google Scholar PubMed PubMed Central

[41] Camarasa CG, Cobo F. Chapter twelve - Application of MALDI-TOF mass spectrometry in clinical virology. In: Cobo F, editor. The use of mass spectrometry technology (MALDI-TOF) in clinical microbiology. Cambridge, MA: Academic Press; 2018. p. 167–80. [cited 2024 Sep 22]. https://www.sciencedirect.com/science/article/pii/B9780128144510000125.10.1016/B978-0-12-814451-0.00012-5Suche in Google Scholar

[42] Bader JC, Lakota EA, Flanagan S, Ong V, Sandison T, Rubino CM, et al. Overcoming the resistance hurdle: Pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin (CD101) against Candida albicans and Candida glabrata. Antimicrob Agents Chemother. 2018 May;62(6):e02614–7.10.1128/AAC.02614-17Suche in Google Scholar PubMed PubMed Central

[43] Cassagne C, Normand AC, L’Ollivier C, Ranque S, Piarroux R. Performance of MALDI-TOF MS platforms for fungal identification. Mycoses. 2016 Nov;59(11):678–90.10.1111/myc.12506Suche in Google Scholar PubMed

[44] Patel R. Matrix-assisted laser desorption ionization-time of flight mass spectrometry in clinical microbiology. Clin Infect Dis Publ Infect Dis Soc Am. 2013 Aug;57(4):564–72.10.1093/cid/cit247Suche in Google Scholar PubMed

[45] Wieser A, Schneider L, Jung J, Schubert S. MALDI-TOF MS in microbiological diagnostics – identification of microorganisms and beyond (mini review). Appl Microbiol Biotechnol. 2012;93(3):965–74.10.1007/s00253-011-3783-4Suche in Google Scholar PubMed

[46] Marklein G, Josten M, Klanke U, Müller E, Horré R, Maier T, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol. 2009 Sep;47(9):2912–7.10.1128/JCM.00389-09Suche in Google Scholar PubMed PubMed Central

[47] Bizzini A, Greub G. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, a revolution in clinical microbial identification. Clin Microbiol Infect Publ Eur Soc Clin Microbiol Infect Dis. 2010 Nov;16(11):1614–9.10.1111/j.1469-0691.2010.03311.xSuche in Google Scholar PubMed

[48] van Veen SQ, Claas ECJ, Kuijper EJ. High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization-time of flight mass spectrometry in conventional medical microbiology laboratories. 2010;48:900–7. PubMed [Internet]. [cited 2024 Sep 22] https://pubmed.ncbi.nlm.nih.gov/20053859/.10.1128/JCM.02071-09Suche in Google Scholar PubMed PubMed Central

[49] Normand AC, Cassagne C, Gautier M, Becker P, Ranque S, Hendrickx M, et al. Decision criteria for MALDI-TOF MS-based identification of filamentous fungi using commercial and in-house reference databases. BMC Microbiol. 2017 Jan;17(1):25.10.1186/s12866-017-0937-2Suche in Google Scholar PubMed PubMed Central

[50] Periyasamy M, Patel H, Lai CF, Nguyen VTM, Nevedomskaya E, Harrod A, et al. APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep. 2015 Oct;13(1):108–21.10.1016/j.celrep.2015.08.066Suche in Google Scholar PubMed PubMed Central

[51] Swiatly A, Plewa S, Matysiak J, Kokot ZJ. Mass spectrometry-based proteomics techniques and their application in ovarian cancer research. J Ovarian Res. 2018 Oct;11:88.10.1186/s13048-018-0460-6Suche in Google Scholar PubMed PubMed Central

[52] Long S, Qin Q, Wang Y, Yang Y, Wang Y, Deng A, et al. Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma. Talanta. 2019 Aug;200:288–92.10.1016/j.talanta.2019.03.067Suche in Google Scholar PubMed

[53] Růžičková T, Vlachová M, Pečinka L, Brychtová M, Večeřa M, Radová L, et al. Detection of early relapse in multiple myeloma patients. Cell Div. 2025 Jan;20(1):4.10.1186/s13008-025-00143-3Suche in Google Scholar PubMed PubMed Central

[54] Zhou H, He X, Zhao J, Mei Z, Zhang X, Yuan W, et al. A MALDI-TOF mass spectrometry-based method for detection of copy number variations in BRCA1 and BRCA2 genes. Front Mol Biosci. 2023;10:1301652.10.3389/fmolb.2023.1301652Suche in Google Scholar PubMed PubMed Central

[55] Yan S, Zheng H, Zhao J, Gao M, Zhang X. Quantification of GPC1(+) exosomes based on MALDI-TOF MS in situ signal amplification for pancreatic cancer discrimination and evaluation. Anal Chem. 2023 Jul;95(27):10196–203.10.1021/acs.analchem.3c00193Suche in Google Scholar PubMed

[56] Li Z, Chen J, Xu B, Zhao W, Zha H, Han Y, et al. Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy. Clin Proteom. 2024 Dec;21(1):35.10.1186/s12014-024-09483-8Suche in Google Scholar PubMed PubMed Central

[57] Fang E, Qian L, Tang J, Tong Z. Cytoplasmic expression of UTP23 promotes colorectal cancer progression. Cell Mol Biol. 2024 Jan;70(1):239–45.10.14715/cmb/2024.70.1.33Suche in Google Scholar PubMed

[58] Zhu Y, Gasilova N, Jović M, Qiao L, Liu B, Tissières Lovey L, et al. Detection of antimicrobial resistance-associated proteins by titanium dioxide-facilitated intact bacteria mass spectrometry. Chem Sci. 2018;9(8):2212–21.10.1039/C7SC04089JSuche in Google Scholar

[59] Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005 Nov;102(44):15785–90.10.1073/pnas.0507816102Suche in Google Scholar PubMed PubMed Central

[60] Kim JI, Noh JY, Kim M, Park JM, Song HW, Kang MJ, et al. Newborn screening by matrix-assisted laser desorption/ionization mass spectrometry based on parylene-matrix chip. Anal Biochem. 2017 Aug;530:31–9.10.1016/j.ab.2017.04.021Suche in Google Scholar PubMed

[61] Naubourg P, El Osta M, Rageot D, Grunewald O, Renom G, Ducoroy P, et al. A multicentre pilot study of a two-tier newborn sickle cell disease screening procedure with a first tier based on a fully automated MALDI-TOF MS platform. Int J Neonatal Screen. 2019 Mar;5(1):10.10.3390/ijns5010010Suche in Google Scholar PubMed PubMed Central

[62] El Osta M, Benoist JF, Naubourg P, Bonacorsi S, Messine R, Ducoroy P, et al. MALDI-MS in first-line screening of newborns for sickle cell disease: results from a prospective study in comparison to HPLC. Clin Chem Lab Med. 2024 Dec;62(6):1149–57.10.1515/cclm-2023-1250Suche in Google Scholar PubMed

[63] Huang L, Zhang Q, Ye Y, Long Y, Huang H, Niu C, et al. Rapid detection of genetic modifiers of β-thalassemia based on MALDI-TOF MS. Ann Hematol. 2025 Mar;104(3):1481–92.10.1007/s00277-025-06277-2Suche in Google Scholar PubMed PubMed Central

[64] Renoux C, Roland E, Ruet S, Zouaghi S, Michel M, Joly P, et al. Evaluation of a new tandem mass spectrometry method for sickle cell disease newborn screening. Int J Neonatal Screen. 2024 Nov;10(4):77.10.3390/ijns10040077Suche in Google Scholar PubMed PubMed Central

[65] Meng Q, Ge S, Yan W, Li R, Dou J, Wang H, et al. Screening for potential serum-based proteomic biomarkers for human type 2 diabetes mellitus using MALDI-TOF MS. Proteom – Clin Appl. 2017;11(3–4):1600079.10.1002/prca.201600079Suche in Google Scholar PubMed

[66] Wan M, Wang Y, Zhan L, Fan J, Hu TY. MALDI-TOF mass spectrometry-based quantification of C-peptide in diabetes patients. Eur J Mass Spectrom. 2019;25(4):345–50. [cited 2024 Sep 16] https://journals.sagepub.com/doi/abs/10.1177/1469066719865265.Suche in Google Scholar

[67] Zawada A, Naskręt D, Matuszewska E, Kokot Z, Grzymisławski M, Zozulińska-Ziółkiewicz D, et al. MALDI-TOF protein profiling reflects changes in type 1 diabetes patients depending on the increased amount of adipose tissue, poor control of diabetes and the presence of chronic complications. Int J Environ Res Public Health. 2021 Jan;18(5):2263.10.3390/ijerph18052263Suche in Google Scholar PubMed PubMed Central

[68] Sánchez-Valencia PE, Díaz-García JD, Leyva-Leyva M, Sánchez-Aguillón F, González-Arenas NR, Mendoza-García JG, et al. Frequency of tumor necrosis factor-α, interleukin-6, and interleukin-10 gene polymorphisms in Mexican patients with diabetic retinopathy and diabetic kidney disease. Pathophysiol J Int Soc Pathophysiol. 2025 Apr;32(2):14.10.3390/pathophysiology32020014Suche in Google Scholar PubMed PubMed Central

[69] Jiang M, Li W, Wang D, Wu X, Chen D, Feng Y. Identification and investigation of protein-related molecules in patients with hyperlipidemia using label-free combined with bioinformatics analysis. Cell Mol Biol. 2023 Dec;69(13):262–9.10.14715/cmb/2023.69.13.39Suche in Google Scholar PubMed

[70] Grela A, Turek A, Piekoszewski W. Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in Alzheimer’s disease. Clin Chem Lab Med. 2012 Feb;50(8):1297–304.10.1515/cclm-2011-0550Suche in Google Scholar PubMed

[71] Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993 Nov;61(5):1965–8.10.1111/j.1471-4159.1993.tb09841.xSuche in Google Scholar PubMed

[72] Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018 Feb;554(7691):249–54.10.1038/nature25456Suche in Google Scholar PubMed

[73] Xing X, Ji X, Liu X, Jin X, He Z, Xu A, et al. Development and validation of a one-step SMN assay for genetic testing in spinal muscular atrophy via MALDI-TOF MS. Analyst. 2024 Dec;150(1):142–53.10.1039/D4AN01225ASuche in Google Scholar PubMed

[74] Deulofeu M, Peña-Méndez EM, Vaňhara P, Havel J, Moráň L, Pečinka L, et al. Discriminating fingerprints of chronic neuropathic pain following spinal cord injury using artificial neural networks and mass spectrometry analysis of female mice serum. Neurochem Int. 2024 Dec;181:105890.10.1016/j.neuint.2024.105890Suche in Google Scholar PubMed

[75] Zhao C, Sun Z, Wang S, Zhang J, Liu J, Chen L, et al. IgG4 glycosylation contributes to the pathogenesis of IgG4 Hashimoto’s thyroiditis via the complement pathway. Eur Thyroid J. 2024 Oct;13(5):e240156.10.1530/ETJ-24-0156Suche in Google Scholar PubMed PubMed Central

[76] Gao S, Jia M, Wang J, Sun Q, Liu F, Yu L, et al. Association of ADAMTS-5 gene polymorphisms with the susceptibility to knee osteoarthritis in a Chinese Han population. J Orthop Surg. 2024 Aug;19(1):513.10.1186/s13018-024-05023-0Suche in Google Scholar PubMed PubMed Central

[77] Oviaño M, Rodríguez-Sánchez B, Gómara M, Alcalá L, Zvezdanova E, Ruíz A, et al. Direct identification of clinical pathogens from liquid culture media by MALDI-TOF MS analysis. Clin Microbiol Infect Publ Eur Soc Clin Microbiol Infect Dis. 2018 Jun;24(6):624–9.10.1016/j.cmi.2017.09.010Suche in Google Scholar PubMed

[78] Schuster D, Josten M, Janssen K, Bodenstein I, Albert C, Schallenberg A, et al. Detection of methicillin-resistant coagulase-negative staphylococci harboring the class A mec complex by MALDI-TOF mass spectrometry. Int J Med Microbiol IJMM. 2018 Jul;308(5):522–6.10.1016/j.ijmm.2018.05.001Suche in Google Scholar PubMed

[79] Rodríguez-Sánchez B, Cercenado E, Coste AT, Greub G. Review of the impact of MALDI-TOF MS in public health and hospital hygiene, 2018. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2019 Jan;24(4):1800193.10.2807/1560-7917.ES.2019.24.4.1800193Suche in Google Scholar PubMed PubMed Central

[80] Nwabufo CK, Aigbogun OP. Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease. J Neurol. 2022;269(11):5762–86.10.1007/s00415-022-11267-9Suche in Google Scholar PubMed PubMed Central

[81] Swales JG, Tucker JW, Strittmatter N, Nilsson A, Cobice D, Clench MR, et al. Mass spectrometry imaging of cassette-dosed drugs for higher throughput pharmacokinetic and biodistribution analysis. Anal Chem. 2014 Aug;86(16):8473–80.10.1021/ac502217rSuche in Google Scholar PubMed

[82] Herkt M, Foinquinos A, Batkai S, Thum T, Pich A. Pharmacokinetic studies of antisense oligonucleotides using MALDI-TOF mass spectrometry. Front Pharmacol. 2020 Mar;11:220. [cited 2024 Sep 16] https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00220/full.10.3389/fphar.2020.00220Suche in Google Scholar PubMed PubMed Central

[83] Zhang N, Baran A, Valioglu F, Teng L, Atalar MN, Keskin C, et al. Antioxidant, AChE inhibitory, and anticancer effects of Verbascum thapsus extract. Cell Mol Biol. 2023 Dec;69(14):211–6.10.14715/cmb/2023.69.14.35Suche in Google Scholar PubMed

[84] Xu W, Qian J, Xu Q, Cai R, Yang G, Wei J, et al. Proteins and signaling pathways response to Wenjingtongluo drug-contained serum in IHUVECs: An explorative proteomic study. Cell Mol Biol. 2023 Jun;69(6):116–24.10.14715/cmb/2023.69.6.18Suche in Google Scholar PubMed

[85] Hamidi H, Bagheri Nejad R, Es-Haghi A, Ghassempour A. A combination of MALDI-TOF MS proteomics and species-unique biomarkers’ discovery for rapid screening of brucellosis. J Am Soc Mass Spectrom. 2022;33(10):1530–9. [cited 2024 Sep 22] https://pubs.acs.org/doi/abs/10.1021/jasms.2c00110.10.1021/jasms.2c00110Suche in Google Scholar PubMed

[86] Vestal M, Hayden K. High performance MALDI-TOF mass spectrometry for proteomics. Int J Mass Spectrom. 2007 Dec;268(2–3):83–92.10.1016/j.ijms.2007.06.021Suche in Google Scholar

[87] Spraggins JM, Rizzo DG, Moore JL, Noto MJ, Skaar EP, Caprioli RM. Next-generation technologies for spatial proteomics: Integrating ultra-high speed MALDI-TOF and high mass resolution MALDI FTICR imaging mass spectrometry for protein analysis. Proteomics. 2016 Jun;16(11–12):1678–89.10.1002/pmic.201600003Suche in Google Scholar PubMed PubMed Central

[88] Abreu R, Matos A, Capela L, Jorge R, Guerreiro JF, Pereira G, et al. Extended-spectrum β-lactamase-producing Klebsiella pneumoniae in dogs from Cape Verde and São Tomé and Príncipe: Implications for public health. Antibiotics Basel Switz. 2025 Apr 16;14(4):408.10.3390/antibiotics14040408Suche in Google Scholar PubMed PubMed Central

[89] Jiwaganont P, Roytrakul S, Thaisakun S, Sukumolanan P, Petchdee S. Investigation of coagulation and proteomics profiles in symptomatic feline hypertrophic cardiomyopathy and healthy control cats. BMC Vet Res. 2024 Jul 5;20(1):292.10.1186/s12917-024-04170-0Suche in Google Scholar PubMed PubMed Central

[90] Hisirová S, Koščová J, Király J, Hajdučková V, Hudecová P, Lauko S, et al. Resistance genes and virulence factor genes in coagulase-negative and positive staphylococci of the staphylococcus intermedius Group (SIG) isolated from the dog skin. Microorganisms. 2025 Mar;13(4):735.10.3390/microorganisms13040735Suche in Google Scholar PubMed PubMed Central

[91] Becker P, Normand AC, Vanantwerpen G, Vanrobaeys M, Haesendonck R, Vercammen F, et al. Identification of fungal isolates by MALDI-TOF mass spectrometry in veterinary practice: Validation of a web application. J Vet Diagn Investig Publ Am Assoc Vet Lab Diagn Inc. 2019 Dec;31(3):471–4.10.1177/1040638719835577Suche in Google Scholar PubMed PubMed Central

[92] Hollemeyer K, Altmeyer W, Heinzle E, Pitra C. Species identification of Oetzi’s clothing with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry based on peptide pattern similarities of hair digests. Rapid Commun Mass Spectrom RCM. 2008 Sep;22(18):2751–67.10.1002/rcm.3679Suche in Google Scholar PubMed

[93] Mark L, Zoltán P, Vaczy A, Lorand T, Marcsik A. High-throughput mass spectrometric analysis of 1400-year-old mycolic acids as biomarkers for ancient tuberculosis infection. J Archaeol Sci. 2010 Feb;37:302–5.10.1016/j.jas.2009.09.041Suche in Google Scholar

[94] Boros-Major A, Bona A, Lovász G, Molnar E, Marcsik A, Pálfi G, et al. New perspectives in biomolecular paleopathology of ancient tuberculosis: A proteomic approach. J Archaeol Sci. 2011 Jan;38:197–201.10.1016/j.jas.2010.09.008Suche in Google Scholar

[95] Hajdu T, Fóthi E, Kovári I, Merczi M, Molnár A, Maász G, et al. Bone tuberculosis in Roman Period Pannonia (western Hungary). Mem Inst Oswaldo Cruz. 2012 Dec;107(8):1048–53.10.1590/S0074-02762012000800014Suche in Google Scholar PubMed

[96] Taylor G, Blau S, Mays S, Monot M, Lee O, Minnikin D, et al. Mycobacterium leprae genotype amplified from an archaeological case of lepromatous leprosy in Central Asia. J Archaeol Sci. 2009 Oct;36(10):2408–14.10.1016/j.jas.2009.06.026Suche in Google Scholar

[97] Stauning MA, Jensen CS, Staalsøe T, Kurtzhals JAL. Detection and quantification of Plasmodium falciparum in human blood by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: A proof of concept study. Malar J. 2023 Sep 26;22(1):285.10.1186/s12936-023-04719-8Suche in Google Scholar PubMed PubMed Central

[98] Inwood J. Identifying malaria in ancient human remains. A molecular and biochemical approach [Doctoral dissertation]. New Haven, CT: Yale University; 2017.Suche in Google Scholar

[99] Ayyadurai S, Flaudrops C, Raoult D, Drancourt M. Rapid identification and typing of Yersinia pestis and other Yersinia species by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. BMC Microbiol. 2010 Nov;10(1):285.10.1186/1471-2180-10-285Suche in Google Scholar PubMed PubMed Central

[100] Mai B, Drancourt M, Aboudharam G. Ancient dental pulp: Masterpiece tissue for paleomicrobiology. Mol Genet Genomic Med. 2020 Mar;8:e1202.10.1002/mgg3.1202Suche in Google Scholar PubMed PubMed Central

[101] Appelt S, Armougom F, Bailly ML, Robert C, Drancourt M. Polyphasic analysis of a middle ages coprolite microbiota, Belgium. PLoS One. 2014 Feb;9(2):e88376.10.1371/journal.pone.0088376Suche in Google Scholar PubMed PubMed Central

[102] Bona Á, Papai Z, Maasz G, Toth GA, Jambor E, Schmidt J, et al. Mass spectrometric identification of ancient proteins as potential molecular biomarkers for a 2000-year-old osteogenic sarcoma. PLoS One. 2014;9(1):e87215. 10.1371/journal.pone.0087215.Suche in Google Scholar PubMed PubMed Central

[103] Çağatay İT. Use of proteomic-based MALDI-TOF mass spectra for identification of bacterial pathogens in aquaculture: A review. Aquac Int. 2024 Dec;32(6):7835–71.10.1007/s10499-024-01544-xSuche in Google Scholar

[104] Zwies C, Vargas Rodríguez ÁM, Naumann M, Seifert F, Pietzsch M. Alternative strategies for the recombinant synthesis, DOPA modification and analysis of mussel foot proteins - A case study for Mefp-3 from Mytilus edulis. Protein Expr Purif. 2024 Jul;219:106483.10.1016/j.pep.2024.106483Suche in Google Scholar PubMed

[105] De Pascale S, Garro G, Pellicano SI, Scaloni A, Carpino S, Caira S, et al. Integrated gel electrophoresis and mass spectrometry approach for detecting and quantifying extraneous milk in protected designation of origin Buffalo Mozzarella Cheese. Foods Basel Switz. 2025 Mar 28;14(7):1193.10.3390/foods14071193Suche in Google Scholar PubMed PubMed Central

[106] Augustyńska-Prejsnar A, Kačániová M, Hanus P, Sokołowicz Z, Słowiński M. Microbial and sensory quality changes in broiler chicken breast meat during refrigerated storage. Foods. 2024;13:4063. [Internet]. [cited 2025 May 12]. https://www.mdpi.com/2304-8158/13/24/4063.10.3390/foods13244063Suche in Google Scholar PubMed PubMed Central

[107] Tamura H. Bacterial pesticides: Mechanism of action, possibility of food contamination, and residue analysis using MS. J Pestic Sci. 2024;49(3):135–47.10.1584/jpestics.D24-006Suche in Google Scholar PubMed PubMed Central

[108] Duncan M, DeMarco ML. MALDI-MS: Emerging roles in pathology and laboratory medicine. Clin Mass Spectrom. 2019 May;13:1–4.10.1016/j.clinms.2019.05.003Suche in Google Scholar PubMed PubMed Central

[109] Seng P, Abat C, Rolain JM, Colson P, Lagier JC, Gouriet F, et al. Identification of rare pathogenic bacteria in a clinical microbiology laboratory: impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2013 Jul;51(7):2182–94.10.1128/JCM.00492-13Suche in Google Scholar PubMed PubMed Central

[110] van Belkum A, Chatellier S, Girard V, Pincus D, Deol P, Dunne WM. Progress in proteomics for clinical microbiology: MALDI-TOF MS for microbial species identification and more. Expert Rev Proteom. 2015;12(6):595–605.10.1586/14789450.2015.1091731Suche in Google Scholar PubMed

[111] Vrioni G, Tsiamis C, Oikonomidis G, Theodoridou K, Kapsimali V, Tsakris A. MALDI-TOF mass spectrometry technology for detecting biomarkers of antimicrobial resistance: current achievements and future perspectives. Ann Transl Med. 2018 Jun;6(12):240.10.21037/atm.2018.06.28Suche in Google Scholar PubMed PubMed Central

[112] Yamin D, Uskoković V, Wakil AM, Goni MD, Shamsuddin SH, Mustafa FH, et al. Current and future technologies for the detection of antibiotic-resistant bacteria. Diagnostics. 2023 Oct;13(20):3246.10.3390/diagnostics13203246Suche in Google Scholar PubMed PubMed Central

[113] Rychert J. Benefits and limitations of MALDI-TOF mass spectrometry for the identification of microorganisms. J Infect Epidemiol. 2019 Feb;2(4):1–5. [cited 2025 May 11] https://www.infectiologyjournal.com/articles/benefits-and-limitations-of-malditof-mass-spectrometry-for-the-identification-of-microorganisms.html?utm_source=chatgpt.com.10.29245/2689-9981/2019/4.1142Suche in Google Scholar

[114] van den Beld MJC, Rossen JWA, Evers N, Kooistra-Smid MAMD, Reubsaet FAG. MALDI-TOF MS using a custom-made database, biomarker assignment, or mathematical classifiers does not differentiate Shigella spp. and Escherichia coli. Microorganisms. 2022 Feb;10(2):435.10.3390/microorganisms10020435Suche in Google Scholar PubMed PubMed Central

[115] Martiny D, Busson L, Wybo I, El Haj RA, Dediste A, Vandenberg O. Comparison of the Microflex LT and Vitek MS systems for routine identification of bacteria by matrix-assisted laser desorption ionization–time of flight mass spectrometry. J Clin Microbiol. 2012 Apr;50(4):1313–25.10.1128/JCM.05971-11Suche in Google Scholar PubMed PubMed Central

[116] Cleaning procedure for MALDI sample targets [Internet]. [cited 2025 May 11]. https://www.ssi.shimadzu.com/service-support/technical-support/handling-precautions/maldi/fleximass/index.html.Suche in Google Scholar

Received: 2024-10-01
Revised: 2025-05-17
Accepted: 2025-05-28
Published Online: 2025-07-18

© 2025 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Heat stroke associated with novel leukaemia inhibitory factor receptor gene variant in a Chinese infant
  2. PSME2 exacerbates ulcerative colitis by disrupting intestinal barrier function and promoting autophagy-dependent inflammation
  3. Can coronavirus disease 2019 affect male fertility or cause spontaneous abortion? A two-sample Mendelian randomization analysis
  4. Biomedical Sciences
  5. Mechanism of triptolide regulating proliferation and apoptosis of hepatoma cells by inhibiting JAK/STAT pathway
  6. Maslinic acid improves mitochondrial function and inhibits oxidative stress and autophagy in human gastric smooth muscle cells
  7. Comparative analysis of inflammatory biomarkers for the diagnosis of neonatal sepsis: IL-6, IL-8, SAA, CRP, and PCT
  8. Post-pandemic insights on COVID-19 and premature ovarian insufficiency
  9. Proteome differences of dental stem cells between permanent and deciduous teeth by data-independent acquisition proteomics
  10. Optimizing a modified cetyltrimethylammonium bromide protocol for fungal DNA extraction: Insights from multilocus gene amplification
  11. Preliminary analysis of the role of small hepatitis B surface proteins mutations in the pathogenesis of occult hepatitis B infection via the endoplasmic reticulum stress-induced UPR-ERAD pathway
  12. Efficacy of alginate-coated gold nanoparticles against antibiotics-resistant Staphylococcus and Streptococcus pathogens of acne origins
  13. Battling COVID-19 leveraging nanobiotechnology: Gold and silver nanoparticle–B-escin conjugates as SARS-CoV-2 inhibitors
  14. Neurodegenerative diseases and neuroinflammation-induced apoptosis
  15. Impact of fracture fixation surgery on cognitive function and the gut microbiota in mice with a history of stroke
  16. COLEC10: A potential tumor suppressor and prognostic biomarker in hepatocellular carcinoma through modulation of EMT and PI3K-AKT pathways
  17. High-temperature requirement serine protease A2 inhibitor UCF-101 ameliorates damaged neurons in traumatic brain-injured rats by the AMPK/NF-κB pathway
  18. SIK1 inhibits IL-1β-stimulated cartilage apoptosis and inflammation in vitro through the CRTC2/CREB1 signaling
  19. Rutin–chitooligosaccharide complex: Comprehensive evaluation of its anti-inflammatory and analgesic properties in vitro and in vivo
  20. Knockdown of Aurora kinase B alleviates high glucose-triggered trophoblast cells damage and inflammation during gestational diabetes
  21. Calcium-sensing receptors promoted Homer1 expression and osteogenic differentiation in bone marrow mesenchymal stem cells
  22. ABI3BP can inhibit the proliferation, invasion, and epithelial–mesenchymal transition of non-small-cell lung cancer cells
  23. Changes in blood glucose and metabolism in hyperuricemia mice
  24. Rapid detection of the GJB2 c.235delC mutation based on CRISPR-Cas13a combined with lateral flow dipstick
  25. IL-11 promotes Ang II-induced autophagy inhibition and mitochondrial dysfunction in atrial fibroblasts
  26. Short-chain fatty acid attenuates intestinal inflammation by regulation of gut microbial composition in antibiotic-associated diarrhea
  27. Application of metagenomic next-generation sequencing in the diagnosis of pathogens in patients with diabetes complicated by community-acquired pneumonia
  28. NAT10 promotes radiotherapy resistance in non-small cell lung cancer by regulating KPNB1-mediated PD-L1 nuclear translocation
  29. Phytol-mixed micelles alleviate dexamethasone-induced osteoporosis in zebrafish: Activation of the MMP3–OPN–MAPK pathway-mediating bone remodeling
  30. Association between TGF-β1 and β-catenin expression in the vaginal wall of patients with pelvic organ prolapse
  31. Primary pleomorphic liposarcoma involving bilateral ovaries: Case report and literature review
  32. Effects of de novo donor-specific Class I and II antibodies on graft outcomes after liver transplantation: A pilot cohort study
  33. Sleep architecture in Alzheimer’s disease continuum: The deep sleep question
  34. Ephedra fragilis plant extract: A groundbreaking corrosion inhibitor for mild steel in acidic environments – electrochemical, EDX, DFT, and Monte Carlo studies
  35. Langerhans cell histiocytosis in an adult patient with upper jaw and pulmonary involvement: A case report
  36. Inhibition of mast cell activation by Jaranol-targeted Pirin ameliorates allergic responses in mouse allergic rhinitis
  37. Aeromonas veronii-induced septic arthritis of the hip in a child with acute lymphoblastic leukemia
  38. Clusterin activates the heat shock response via the PI3K/Akt pathway to protect cardiomyocytes from high-temperature-induced apoptosis
  39. Research progress on fecal microbiota transplantation in tumor prevention and treatment
  40. Low-pressure exposure influences the development of HAPE
  41. Stigmasterol alleviates endplate chondrocyte degeneration through inducing mitophagy by enhancing PINK1 mRNA acetylation via the ESR1/NAT10 axis
  42. AKAP12, mediated by transcription factor 21, inhibits cell proliferation, metastasis, and glycolysis in lung squamous cell carcinoma
  43. Association between PAX9 or MSX1 gene polymorphism and tooth agenesis risk: A meta-analysis
  44. A case of bloodstream infection caused by Neisseria gonorrhoeae
  45. Case of nasopharyngeal tuberculosis complicated with cervical lymph node and pulmonary tuberculosis
  46. p-Cymene inhibits pro-fibrotic and inflammatory mediators to prevent hepatic dysfunction
  47. GFPT2 promotes paclitaxel resistance in epithelial ovarian cancer cells via activating NF-κB signaling pathway
  48. Transfer RNA-derived fragment tRF-36 modulates varicose vein progression via human vascular smooth muscle cell Notch signaling
  49. RTA-408 attenuates the hepatic ischemia reperfusion injury in mice possibly by activating the Nrf2/HO-1 signaling pathway
  50. Decreased serum TIMP4 levels in patients with rheumatoid arthritis
  51. Sirt1 protects lupus nephritis by inhibiting the NLRP3 signaling pathway in human glomerular mesangial cells
  52. Sodium butyrate aids brain injury repair in neonatal rats
  53. Interaction of MTHFR polymorphism with PAX1 methylation in cervical cancer
  54. Convallatoxin inhibits proliferation and angiogenesis of glioma cells via regulating JAK/STAT3 pathway
  55. The effect of the PKR inhibitor, 2-aminopurine, on the replication of influenza A virus, and segment 8 mRNA splicing
  56. Effects of Ire1 gene on virulence and pathogenicity of Candida albicans
  57. Small cell lung cancer with small intestinal metastasis: Case report and literature review
  58. GRB14: A prognostic biomarker driving tumor progression in gastric cancer through the PI3K/AKT signaling pathway by interacting with COBLL1
  59. 15-Lipoxygenase-2 deficiency induces foam cell formation that can be restored by salidroside through the inhibition of arachidonic acid effects
  60. FTO alleviated the diabetic nephropathy progression by regulating the N6-methyladenosine levels of DACT1
  61. Clinical relevance of inflammatory markers in the evaluation of severity of ulcerative colitis: A retrospective study
  62. Zinc valproic acid complex promotes osteoblast differentiation and exhibits anti-osteoporotic potential
  63. Primary pulmonary synovial sarcoma in the bronchial cavity: A case report
  64. Metagenomic next-generation sequencing of alveolar lavage fluid improves the detection of pulmonary infection
  65. Uterine tumor resembling ovarian sex cord tumor with extensive rhabdoid differentiation: A case report
  66. Genomic analysis of a novel ST11(PR34365) Clostridioides difficile strain isolated from the human fecal of a CDI patient in Guizhou, China
  67. Effects of tiered cardiac rehabilitation on CRP, TNF-α, and physical endurance in older adults with coronary heart disease
  68. Changes in T-lymphocyte subpopulations in patients with colorectal cancer before and after acupoint catgut embedding acupuncture observation
  69. Modulating the tumor microenvironment: The role of traditional Chinese medicine in improving lung cancer treatment
  70. Alterations of metabolites related to microbiota–gut–brain axis in plasma of colon cancer, esophageal cancer, stomach cancer, and lung cancer patients
  71. Research on individualized drug sensitivity detection technology based on bio-3D printing technology for precision treatment of gastrointestinal stromal tumors
  72. CEBPB promotes ulcerative colitis-associated colorectal cancer by stimulating tumor growth and activating the NF-κB/STAT3 signaling pathway
  73. Oncolytic bacteria: A revolutionary approach to cancer therapy
  74. A de novo meningioma with rapid growth: A possible malignancy imposter?
  75. Diagnosis of secondary tuberculosis infection in an asymptomatic elderly with cancer using next-generation sequencing: Case report
  76. Hesperidin and its zinc(ii) complex enhance osteoblast differentiation and bone formation: In vitro and in vivo evaluations
  77. Research progress on the regulation of autophagy in cardiovascular diseases by chemokines
  78. Anti-arthritic, immunomodulatory, and inflammatory regulation by the benzimidazole derivative BMZ-AD: Insights from an FCA-induced rat model
  79. Immunoassay for pyruvate kinase M1/2 as an Alzheimer’s biomarker in CSF
  80. The role of HDAC11 in age-related hearing loss: Mechanisms and therapeutic implications
  81. Evaluation and application analysis of animal models of PIPNP based on data mining
  82. Therapeutic approaches for liver fibrosis/cirrhosis by targeting pyroptosis
  83. Fabrication of zinc oxide nanoparticles using Ruellia tuberosa leaf extract induces apoptosis through P53 and STAT3 signalling pathways in prostate cancer cells
  84. Haplo-hematopoietic stem cell transplantation and immunoradiotherapy for severe aplastic anemia complicated with nasopharyngeal carcinoma: A case report
  85. Modulation of the KEAP1-NRF2 pathway by Erianin: A novel approach to reduce psoriasiform inflammation and inflammatory signaling
  86. The expression of epidermal growth factor receptor 2 and its relationship with tumor-infiltrating lymphocytes and clinical pathological features in breast cancer patients
  87. Innovations in MALDI-TOF Mass Spectrometry: Bridging modern diagnostics and historical insights
  88. BAP1 complexes with YY1 and RBBP7 and its downstream targets in ccRCC cells
  89. Hypereosinophilic syndrome with elevated IgG4 and T-cell clonality: A report of two cases
  90. Electroacupuncture alleviates sciatic nerve injury in sciatica rats by regulating BDNF and NGF levels, myelin sheath degradation, and autophagy
  91. Polydatin prevents cholesterol gallstone formation by regulating cholesterol metabolism via PPAR-γ signaling
  92. RNF144A and RNF144B: Important molecules for health
  93. Analysis of the detection rate and related factors of thyroid nodules in the healthy population
  94. Artesunate inhibits hepatocellular carcinoma cell migration and invasion through OGA-mediated O-GlcNAcylation of ZEB1
  95. Endovascular management of post-pancreatectomy hemorrhage caused by a hepatic artery pseudoaneurysm: Case report and review of the literature
  96. Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis
  97. SATB2 promotes humeral fracture healing in rats by activating the PI3K/AKT pathway
  98. Overexpression of the ferroptosis-related gene, NFS1, corresponds to gastric cancer growth and tumor immune infiltration
  99. Understanding risk factors and prognosis in diabetic foot ulcers
  100. Atractylenolide I alleviates the experimental allergic response in mice by suppressing TLR4/NF-kB/NLRP3 signalling
  101. FBXO31 inhibits the stemness characteristics of CD147 (+) melanoma stem cells
  102. Immune molecule diagnostics in colorectal cancer: CCL2 and CXCL11
  103. Inhibiting CXCR6 promotes senescence of activated hepatic stellate cells with limited proinflammatory SASP to attenuate hepatic fibrosis
  104. Cadmium toxicity, health risk and its remediation using low-cost biochar adsorbents
  105. Pulmonary cryptococcosis with headache as the first presentation: A case report
  106. Solitary pulmonary metastasis with cystic airspaces in colon cancer: A rare case report
  107. RUNX1 promotes denervation-induced muscle atrophy by activating the JUNB/NF-κB pathway and driving M1 macrophage polarization
  108. Morphometric analysis and immunobiological investigation of Indigofera oblongifolia on the infected lung with Plasmodium chabaudi
  109. The NuA4/TIP60 histone-modifying complex and Hr78 modulate the Lobe2 mutant eye phenotype
  110. Experimental study on salmon demineralized bone matrix loaded with recombinant human bone morphogenetic protein-2: In vitro and in vivo study
  111. A case of IgA nephropathy treated with a combination of telitacicept and half-dose glucocorticoids
  112. Analgesic and toxicological evaluation of cannabidiol-rich Moroccan Cannabis sativa L. (Khardala variety) extract: Evidence from an in vivo and in silico study
  113. Wound healing and signaling pathways
  114. Combination of immunotherapy and whole-brain radiotherapy on prognosis of patients with multiple brain metastases: A retrospective cohort study
  115. To explore the relationship between endometrial hyperemia and polycystic ovary syndrome
  116. Research progress on the impact of curcumin on immune responses in breast cancer
  117. Biogenic Cu/Ni nanotherapeutics from Descurainia sophia (L.) Webb ex Prantl seeds for the treatment of lung cancer
  118. Dapagliflozin attenuates atrial fibrosis via the HMGB1/RAGE pathway in atrial fibrillation rats
  119. Glycitein alleviates inflammation and apoptosis in keratinocytes via ROS-associated PI3K–Akt signalling pathway
  120. ADH5 inhibits proliferation but promotes EMT in non-small cell lung cancer cell through activating Smad2/Smad3
  121. Apoptotic efficacies of AgNPs formulated by Syzygium aromaticum leaf extract on 32D-FLT3-ITD human leukemia cell line with PI3K/AKT/mTOR signaling pathway
  122. Novel cuproptosis-related genes C1QBP and PFKP identified as prognostic and therapeutic targets in lung adenocarcinoma
  123. Bee venom promotes exosome secretion and alters miRNA cargo in T cells
  124. Treatment of pure red cell aplasia in a chronic kidney disease patient with roxadustat: A case report
  125. Comparative bioinformatics analysis of the Wnt pathway in breast cancer: Selection of novel biomarker panels associated with ER status
  126. Kynurenine facilitates renal cell carcinoma progression by suppressing M2 macrophage pyroptosis through inhibition of CASP1 cleavage
  127. RFX5 promotes the growth, motility, and inhibits apoptosis of gastric adenocarcinoma cells through the SIRT1/AMPK axis
  128. ALKBH5 exacerbates early cardiac damage after radiotherapy for breast cancer via m6A demethylation of TLR4
  129. Phytochemicals of Roman chamomile: Antioxidant, anti-aging, and whitening activities of distillation residues
  130. Circadian gene Cry1 inhibits the tumorigenicity of hepatocellular carcinoma by the BAX/BCL2-mediated apoptosis pathway
  131. The TNFR-RIPK1/RIPK3 signalling pathway mediates the effect of lanthanum on necroptosis of nerve cells
  132. Longitudinal monitoring of autoantibody dynamics in patients with early-stage non-small-cell lung cancer undergoing surgery
  133. The potential role of rutin, a flavonoid, in the management of cancer through modulation of cell signaling pathways
  134. Construction of pectinase gene engineering microbe and its application in tobacco sheets
  135. Construction of a microbial abundance prognostic scoring model based on intratumoral microbial data for predicting the prognosis of lung squamous cell carcinoma
  136. Sepsis complicated by haemophagocytic lymphohistiocytosis triggered by methicillin-resistant Staphylococcus aureus and human herpesvirus 8 in an immunocompromised elderly patient: A case report
  137. Sarcopenia in liver transplantation: A comprehensive bibliometric study of current research trends and future directions
  138. Advances in cancer immunotherapy and future directions in personalized medicine
  139. Ecology and Environmental Science
  140. Optimization and comparative study of Bacillus consortia for cellulolytic potential and cellulase enzyme activity
  141. The complete mitochondrial genome analysis of Haemaphysalis hystricis Supino, 1897 (Ixodida: Ixodidae) and its phylogenetic implications
  142. Epidemiological characteristics and risk factors analysis of multidrug-resistant tuberculosis among tuberculosis population in Huzhou City, Eastern China
  143. Indices of human impacts on landscapes: How do they reflect the proportions of natural habitats?
  144. Genetic analysis of the Siberian flying squirrel population in the northern Changbai Mountains, Northeast China: Insights into population status and conservation
  145. Diversity and environmental drivers of Suillus communities in Pinus sylvestris var. mongolica forests of Inner Mongolia
  146. Global assessment of the fate of nitrogen deposition in forest ecosystems: Insights from 15N tracer studies
  147. Fungal and bacterial pathogenic co-infections mainly lead to the assembly of microbial community in tobacco stems
  148. Influencing of coal industry related airborne particulate matter on ocular surface tear film injury and inflammatory factor expression in Sprague-Dawley rats
  149. Temperature-dependent development, predation, and life table of Sphaerophoria macrogaster (Thomson) (Diptera: Syrphidae) feeding on Myzus persicae (Sulzer) (Homoptera: Aphididae)
  150. Agriculture
  151. Integrated analysis of transcriptome, sRNAome, and degradome involved in the drought-response of maize Zhengdan958
  152. Variation in flower frost tolerance among seven apple cultivars and transcriptome response patterns in two contrastingly frost-tolerant selected cultivars
  153. Heritability of durable resistance to stripe rust in bread wheat (Triticum aestivum L.)
  154. Molecular mechanism of follicular development in laying hens based on the regulation of water metabolism
  155. Animal Science
  156. Effect of sex ratio on the life history traits of an important invasive species, Spodoptera frugiperda
  157. Plant Sciences
  158. Hairpin in a haystack: In silico identification and characterization of plant-conserved microRNA in Rafflesiaceae
  159. Widely targeted metabolomics of different tissues in Rubus corchorifolius
  160. The complete chloroplast genome of Gerbera piloselloides (L.) Cass., 1820 (Carduoideae, Asteraceae) and its phylogenetic analysis
  161. Field trial to correlate mineral solubilization activity of Pseudomonas aeruginosa and biochemical content of groundnut plants
  162. Correlation analysis between semen routine parameters and sperm DNA fragmentation index in patients with semen non-liquefaction: A retrospective study
  163. Plasticity of the anatomical traits of Rhododendron L. (Ericaceae) leaves and its implications in adaptation to the plateau environment
  164. Effects of Piriformospora indica and arbuscular mycorrhizal fungus on growth and physiology of Moringa oleifera under low-temperature stress
  165. Effects of different sources of potassium fertiliser on yield, fruit quality and nutrient absorption in “Harward” kiwifruit (Actinidia deliciosa)
  166. Comparative efficiency and residue levels of spraying programs against powdery mildew in grape varieties
  167. The DREB7 transcription factor enhances salt tolerance in soybean plants under salt stress
  168. Using plant electrical signals of water hyacinth (Eichhornia crassipes) for water pollution monitoring
  169. Food Science
  170. Phytochemical analysis of Stachys iva: Discovering the optimal extract conditions and its bioactive compounds
  171. Review on role of honey in disease prevention and treatment through modulation of biological activities
  172. Computational analysis of polymorphic residues in maltose and maltotriose transporters of a wild Saccharomyces cerevisiae strain
  173. Optimization of phenolic compound extraction from Tunisian squash by-products: A sustainable approach for antioxidant and antibacterial applications
  174. Liupao tea aqueous extract alleviates dextran sulfate sodium-induced ulcerative colitis in rats by modulating the gut microbiota
  175. Toxicological qualities and detoxification trends of fruit by-products for valorization: A review
  176. Polyphenolic spectrum of cornelian cherry fruits and their health-promoting effect
  177. Optimizing the encapsulation of the refined extract of squash peels for functional food applications: A sustainable approach to reduce food waste
  178. Advancements in curcuminoid formulations: An update on bioavailability enhancement strategies curcuminoid bioavailability and formulations
  179. Impact of saline sprouting on antioxidant properties and bioactive compounds in chia seeds
  180. The dilemma of food genetics and improvement
  181. Bioengineering and Biotechnology
  182. Impact of hyaluronic acid-modified hafnium metalorganic frameworks containing rhynchophylline on Alzheimer’s disease
  183. Emerging patterns in nanoparticle-based therapeutic approaches for rheumatoid arthritis: A comprehensive bibliometric and visual analysis spanning two decades
  184. Application of CRISPR/Cas gene editing for infectious disease control in poultry
  185. Preparation of hafnium nitride-coated titanium implants by magnetron sputtering technology and evaluation of their antibacterial properties and biocompatibility
  186. Preparation and characterization of lemongrass oil nanoemulsion: Antimicrobial, antibiofilm, antioxidant, and anticancer activities
  187. Corrigendum
  188. Corrigendum to “Utilization of convolutional neural networks to analyze microscopic images for high-throughput screening of mesenchymal stem cells”
  189. Corrigendum to “Effects of Ire1 gene on virulence and pathogenicity of Candida albicans
Heruntergeladen am 4.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/biol-2025-1136/html
Button zum nach oben scrollen